Structural separations of endogenous and exogenous compounds directly from tissue sections by ion mobility \ue2 mass spectrometry by Parson, Whitney Beth
STRUCTURAL SEPARATIONS OF ENDOGENOUS AND EXOGENOUS 
COMPOUNDS DIRECTLY FROM TISSUE SECTIONS 
BY ION MOBILITY – MASS SPECTROMETRY 
 
By 
Whitney Beth Parson 
 
Dissertation 
Submitted to the Faculty of the  
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of  
DOCTOR OF PHILOSOPHY 
in 
Biochemistry 
August, 2010 
Nashville, Tennessee 
Approved: 
Dr. Richard M. Caprioli 
Dr. Daniel C. Liebler 
Dr. John A. McLean 
Dr. David E. Ong 
Dr. David L. Tabb 
     
 
 
 
 
 
 
 
 
 
Copyright  2010 by Whitney Beth Parson 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
 
 
“Today is your day! Your mountain is waiting. So…get on your way.” 
       -Dr. Seuss 
 
 
This work is dedicated to my parents, Jerry and Kathy Ridenour,  
for always believing in me  
and 
 Adam and Chloe Parson  
for their continued encouragement and inspiration. 
 
Thank you. 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
 
 I am truly grateful for all who have provided me with endless support and 
encouragement during my Ph.D. research. First and foremost, I thank my advisor, 
Richard Caprioli, for providing me with the opportunity to be a member of his 
laboratory. I will always cherish the guidance and wisdom that you provided me on 
my path to becoming an independent scientist. I am also indebted to each of my 
committee members:  John McLean, Daniel Liebler, David Ong, and David Tabb. 
Thank you for your advice, guidance, and patience. 
 I must acknowledge the multiple people and groups which I have had the 
pleasure of working with during my thesis. I would like to thank the current and 
former members of the Mass Spectrometry Research Center. Your support and 
encouragement as colleagues, teammates, and friends is truly appreciated. I would 
also like to thank the many collaborators at Vanderbilt University and Waters 
Corporation for their time, wisdom, and samples. I thank John McLean, Larissa 
Fenn, and Michal Kliman from the McLean Laboratory for their collaboration and 
instrumentation. Peter Straub in the Tabb Laboratory assisted with file conversion, 
and analysis of levuglandin adducted peptides was performed in collaboration with 
Almary Chacon and the Oates Laboratory. I thank Michael Cooper, Ty Abel, Reid 
Thompson, and the Molecular Neurosurgical Tissue Bank for tissue samples and 
assistance with pathological evaluation. Of course, this work would not have been 
possible without the financial support provided by the NIH (NIH/NIGMS 
5R01GM58008-10) and the Department of Defense (W81XWH- 05-1-0179).  
v 
 
 I must also acknowledge my wonderful friends and family. To my parents, 
Jerry and Kathy, I thank you for never doubting my success. I know you did 
everything you could to provide me with chances which were not available to you. I 
appreciate that more than you will ever know. Thank you to Jason Ridenour, Kathryn 
Mayforth, and Christina and Jacob Ridenour, for your continued love and support. 
To Adrian Bowman, I thank you for always being there when it counts. 
 Finally, I must thank my best friend and husband, Adam Parson, and our 
beautiful daughter, Chloe. You have both enriched and blessed my life. Adam, thank 
you for the immense love, patience, and encouragement you have provided. I would 
especially like to thank you for sharing Chloe and your wonderful parents, Paul and 
Brenda Parson with me. Chloe, I truly cherish every moment we spend together and 
thank you for always putting a smile on my face. 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
TABLE OF CONTENTS 
 
Page 
DEDICATION ....................................................................................................... iii  
ACKNOWLEDGEMENTS .................................................................................... iv 
LIST OF TABLES ................................................................................................. ix 
LIST OF FIGURES ............................................................................................... x 
LIST OF ABBREVIATIONS ................................................................................ xiii  
Chapter 
I. INTRODUCTION ............................................................................................ 1 
 
  Introduction to Ion Mobility - Mass Spectrometry ................................... 2 
  Direct Analysis of Tissue Sections by Mass Spectrometry ..................... 5 
   Sample preparation ........................................................................... 5 
   Mass spectrometric analysis .............................................................. 9 
   MALDI ion mobility - mass spectrometry ......................................... 11 
  Applications of Tissue Analysis by Mass Spectrometry ....................... 15 
   Protein analysis by MALDI MS ........................................................ 15 
   Analysis of peptides by MALDI MS .................................................. 18 
   Phospholipid analysis by MALDI MS ............................................... 19 
   Analysis of pharmaceutical compounds by MALDI MS ................... 22 
  Summary and Research Objectives ..................................................... 27 
 
II.  PROFILING AND IMAGING OF TISSUES BY MALDI ION MOBILITY - 
 MASS SPECTROMETRY ............................................................................ 30 
   
  Abstract ................................................................................................ 30 
  Introduction .......................................................................................... 30 
  Results ................................................................................................. 32  
   Molecular profiling of tissue sections ............................................... 33 
   Imaging of isobaric species ............................................................. 39 
   Selective imaging of endogenous phospholipids ............................. 41 
   Simultaneous imaging of endogenous phospholipids and  
   tryptic peptides ................................................................................ 43 
  Conclusions.......................................................................................... 45 
  Materials and Methods ......................................................................... 45 
 
 
vii 
 
III. STRUCTURAL CHARACTERIZATION OF PHOSPHOLIPIDS  
 AND PEPTIDES DIRECTLY FROM TISSUE SECTIONS BY  
 MALDI TRAVELING-WAVE ION MOBILITY - MASS  
 SPECTROMETRY ........................................................................................ 53 
   
  Abstract ................................................................................................ 53
  Introduction .......................................................................................... 54 
  Results ................................................................................................. 57 
   Collision cross section calibration of MALDI t-wave IM-MS ............. 60 
   Analysis of phospholipids by MALDI t-wave IM-MS directly 
   from tissue sections ......................................................................... 60 
   Analysis of peptides by MALDI t-wave IM-MS directly 
   from tissue sections ......................................................................... 65 
   Validation of peptide MALDI t-wave IM-MS CCS values ................. 70 
   Analysis of phosphopeptides by MALDI t-wave IM-MS ................... 75 
   Analysis of levuglandin adducted peptides by MALDI t-wave 
   IM-MS .............................................................................................. 79 
   Analysis of farnesylated peptides by MALDI t-wave IM-MS............. 82 
  Conclusions.......................................................................................... 86 
  Materials and Methods ......................................................................... 90 
 
IV.  STRUCTURAL SEPARATIONS OF PHARMACEUTICAL  
 COMPOUNDS BY MALDI ION MOBILITY - MASS SPECTROMETRY ....... 97 
   
  Abstract ................................................................................................ 97 
  Introduction .......................................................................................... 97 
  Results ................................................................................................. 99  
   Collision cross sections of pharmaceutical compounds ................... 99 
   Computational structural analysis of pharmaceutical 
   compounds .................................................................................... 105 
   Simultaneous imaging of small molecules by MALDI 
   t-wave IM-MS/MS .......................................................................... 107 
  Conclusions........................................................................................ 111 
  Materials and Methods ....................................................................... 112 
 
V. CONCLUSIONS AND PERSPECTIVES ...................................................... 117 
  
  Direct Tissue Analysis by MALDI Ion Mobility – Mass 
  Spectrometry ...................................................................................... 117 
  Current applications ........................................................................... 119 
   Lipid selective imaging MALDI ion mobility – mass  
   spectrometry .................................................................................. 119 
   Structural internal standards for exogenous drug imaging ............ 121 
  Future Research Directions................................................................ 123 
   Peptides containing posttranslational modifications ...................... 123 
   Ion mobility selectivity based on drift gas composition .................. 124 
viii 
 
   Advances in MALDI IM-MS instrumentation .................................. 125 
   Differential mobility spectrometry ................................................... 128 
  Conclusions........................................................................................ 129
   
Appendix 
A.  REFERENCES OF ADAPTION FOR CHAPTERS ...................................... 130 
REFERENCES ................................................................................................. 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
  LIST OF TABLES  
 
Table Page 
1. BSA tryptic peptide MALDI drift cell IM-MS CCS external calibrants  
 used for measuring t-wave IM-MS CCS values directly from 
 tissue sections .............................................................................................. 58 
 
2. Phospholipid MALDI drift cell IM-MS CCS internal calibrants 
 used for measuring phospholipid t-wave IM-MS CCS values 
 directly from tissue sections. ........................................................................ 59 
 
3. Phospholipid MALDI t-wave IM-MS CCS values obtained 
 directly from tissue sections ......................................................................... 67 
 
4. Assignment of tryptic peptide sequences and MALDI reported 
 t-wave IM-MS CCS values measured directly from tissue sections ............. 72 
 
5. Tryptic peptide CCS values obtained from standards using MALDI 
 drift cell and t-wave IM-MS ........................................................................... 74 
 
6.  MALDI t-wave IM-MS CCS values of phosphopeptides ............................... 78 
  
7. MALDI t-wave IM-MS CCS values of phosphopeptides obtained 
 directly from a bovine lens extract ................................................................ 81 
 
8. Change in t-wave IM-MS CCS values of peptides due to levuglandin 
 adduction...................................................................................................... 85 
 
9. Change in t-wave IM-MS CCS values of peptides due to farnesylation ....... 88 
 
10.  The eighteen pharmaceutical compounds analyzed and their 
 main chemical moiety, m/z, Ko, and CCS. .................................................. 102  
 
 
 
 
 
 
 
x 
 
LIST OF FIGURES 
 
Figure Page 
1. MALDI IM-MS analysis of a grade II human astrocytoma tissue 
 section. ........................................................................................................... 4 
 
2. General profiling and imaging work-flow schemes for the analysis 
 of biological tissue sections by MALDI MS ..................................................... 7 
 
3. Schematic of the MALDI drift cell IM-TOFMS instrument. ............................ 12 
 
4. Schematic of the MALDI t-wave IM-TOFMS instrument. .............................. 14 
 
5. MALDI MS analysis of a human renal cell carcinoma with attached  
 non-tumor tissue biopsy ............................................................................... 17 
 
6. Molecular imaging of phosphatidylcholine and sphingomyelin on 
 days 4 to 8 of implantation ........................................................................... 21 
 
7. Detection of drug and metabolite distribution in a whole rat sagittal  
 tissue section ............................................................................................... 24 
 
8. Imaging MALDI IM-MS/MS analysis of exogenous pharmaceutical  
 compounds. .................................................................................................. 26 
 
9. Schematic diagram illustrating the data dimensionality in imaging  
 MALDI IM-MS ............................................................................................... 34 
 
10. Molecular profiling of human glioblastoma multiforme tissue 
 sections by MALDI IM-MS ............................................................................ 35 
 
11. Workflow for histology-directed profiling by MALDI IM-MS. .......................... 37 
 
12. Histology-directed profiling of phospholipids and peptides  
 analyzed separately by MALDI TOFMS and simultaneously 
 by MALDI IM-TOFMS ................................................................................... 38 
 
13. Imaging MALDI drift cell IM-MS of a nominally isobaric peptide 
 and phospholipid deposited onto a mouse liver tissue section ..................... 40 
 
14. Selective imaging MALDI drift cell IM-MS for mapping the 
 spatial coordinates of analytes based on structure and m/z. ........................ 42 
 
xi 
 
15. Simultaneous imaging of phospholipids and tryptic peptides 
 directly from a rat brain tissue section. ......................................................... 44 
 
16. A typical 2D td versus m/z conformation plot acquired directly from a 
 rat brain tissue section. ................................................................................ 61 
 
17. Calibration curves of normalized CCS versus effective td used to  
 obtain t-wave IM-MS CCS values of phospholipids and tryptic 
 peptides directly from tissue sections. .......................................................... 62 
 
18. Comparison of the difference in PC t-wave IM-MS CCS values 
 based on using either peptide or phospholipid drift cell IM-MS 
 CCS values as calibrants ............................................................................. 64 
 
19. MALDI t-wave IM-MS of phospholipids acquired directly from  
 tissue sections .............................................................................................. 66 
 
20. Correlation of peptide MALDI drift cell and t-wave IM-MS CCS 
 values ........................................................................................................... 69 
 
21. MALDI t-wave IM-MS CCS versus m/z correlations of tryptic 
 peptides acquired directly from tissue sections ............................................ 71 
 
22. Validation of peptide MALDI t-wave IM-MS CCS values obtained 
 directly from tissue sections ......................................................................... 73 
 
23. Example of the shift in CCS and m/z of phosphopeptides in 
 relation to unmodified peptides .................................................................... 76 
 
24. MALDI t-wave IM-MS of tryptic peptides and phosphopeptides ................... 77 
 
25. MALDI t-wave IM-MS of tryptic -crystallin peptides and 
 phosphopeptides acquired directly from a bovine lens extract ..................... 80 
 
26. Structures of the levuglandin adducts formed from the reaction 
 of LGE2 with the -amino group of lysine or the -amino of 
 the peptide n-terminus ................................................................................. 83 
 
27. MALDI t-wave IM-MS of levuglandin adducted peptide standards ............... 84 
 
28. MALDI t-wave IM-MS of farnesylated peptide standards ............................. 87 
 
29.  Chemical structures of the eighteen pharmaceutical compounds 
 analyzed by MALDI drift cell IM-MS ........................................................... 100 
 
 
xii 
 
30.  Plot of ion-neutral CCS values versus m/z correlations for eighteen  
 pharmaceutical compounds ....................................................................... 101   
 
 
31. 2D conformation plots of metoprolol, atenolol, clozapine, and 
 clozapine N-oxide ....................................................................................... 104 
 
32. 2D conformation plot comparing CCS values obtained by MALDI 
 drift cell IM-MS and in silico simulations of extended and 
 compact conformations of seven pharmaceutical compounds ................... 106 
 
33.  Simultaneous analysis of four drug compounds deposited onto a  
 mouse liver tissue section by MALDI t-wave IM-MS/MS ............................ 108 
 
34.  Fragment m/z and td specific images of four drug 
      compounds deposited onto a mouse tissue section by MALDI  
 t-wave IM-MS/MS ....................................................................................... 110 
 
35. Phospholipid selective imaging by MALDI IM-MS directly from  
 a grade II human clear cell renal cell carcinoma tissue section 
 with adjacent non-tumor cortex region ....................................................... 120 
 
36. Imaging of isobaric phospholipid species by MALDI MS/MS ...................... 122 
 
37.  Gas-phase separation of enantiomers ....................................................... 126 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
LIST OF ABREVIATIONS 
 
2D, two-dimensional 
ATD, arrival time distribution  
CCS, collision cross section 
CHCA, -cyano-4-hydroxycinnamic acid 
Da, Dalton 
DHB, 2, 5-dihydroxybenzoic acid 
DMS, differential mobility spectrometry 
ESI, electrospray ionization 
FTICR, Fourier transform ion cyclotron resonance 
GBM, glioblastoma multiforme 
HPLC, high performance liquid chromatography 
IMS, imaging mass spectrometry 
IS, internal standard 
LG, levuglandin 
IM-MS, ion mobility - mass spectrometry 
m/z, mass-to-charge 
MALDI, matrix-assisted laser desorption/ionization 
MS, mass spectrometry 
PC, phosphatidylcholine 
PCE, phosphatidylcholine extract 
PK, pharmacokinetic 
xiv 
 
PTM, posttranslational modification 
SA, sinapinic acid 
SM, sphingomyelin 
S/N, signal-to-noise 
SRM, single reaction monitoring 
STP, standard temperature pressure 
td, drift time 
t-wave , traveling-wave 
TIC, total ion current 
TOF, time-of-flight 
WBA, whole body autoradiography 
1 
 
CHAPTER I 
 
INTRODUCTION 
 
 Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) 
can provide the spatial distribution, relative abundance, and molecular identity of 
thousands of endogenous or exogenous analytes (proteins, lipids, peptides, 
pharmaceutical compounds, and metabolites) directly from tissue sections.1-6 An 
advantage of MALDI MS for determining the spatial distribution of compounds is that 
analysis can be performed without the need for prior knowledge or specific targeted 
reagents such as antibodies. Tissue analysis by MALDI MS has been utilized for a 
variety of applications including studying the underlying molecular mechanisms of 
biological processes,5, 6 and obtaining pharmacokinetic information directly from 
dosed animal tissue sections.3, 7 Further, MALDI MS is currently used in clinical and 
medical research where it has been successfully applied to the molecular analysis of 
diseases such as cancer and to aid in the assessment of clinical diagnosis and 
prognosis.2, 8-10  
 Due to the complex nature of tissue samples, additional analyte separation is 
required to increase the specificity of MALDI MS for analytes of interest. To attack 
this problem, we hypothesize that a rapid post-ionization gas-phase separation by 
ion mobility (IM) spectrometry can be performed prior to MS analysis. We propose 
that the additional dimension of separation by IM will enhance tissue analysis by 
providing the ability to separate analytes of interest from other components in the 
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sample (chemical noise), structurally separate phospholipid and peptide species, 
elucidate analyte structural information, and perform simultaneous fractionation of all 
analytes detected directly from tissue sections. After a brief introduction to MALDI 
IM-MS, the following sections will focus on the current state of MALDI MS 
technology in terms of tissue sample preparation and instrumentation. Further, 
examples of current MALDI MS applications for direct tissue analysis, and the 
benefits of enhancing MALDI MS analysis with an additional dimension of separation 
by IM will be described.  
 
Introduction to Ion Mobility - Mass Spectrometry 
 Two-dimensional (2D) separations performed by IM-MS are based on 
structure or apparent surface area in the mobility cell and m/z in the MS analyzer.11-
15 Analytes traverse the IM cell under low electric field conditions, and their progress 
is impeded by the neutral gas molecules. Analytes with larger gas-phase structures 
traverse the IM cell more slowly and have larger drift time (td, the amount of time the 
analyte traverses the IM chamber) values than analytes with more compact 
structures. The rapid (μs-ms) ion fractionation step performed by IM can enhance 
tissue analysis by providing an additional dimension of separation and information 
on the gas-phase structure of analytes in the form of a collision cross section (CCS, 
Å2). For the analysis of complex samples which contain multiple isobaric molecular 
species, such as tissue sections, the 2D separation provides the ability to structurally 
resolve and distinguish between species of the same m/z. Further, different classes 
of biomolecules detected from tissue sections can be resolved by MALDI IM-MS 
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based on their intrinsic gas-phase packing efficiencies along td versus m/z 
correlations termed trend-lines.16, 17 Figure 1a illustrates the separation of 
phospholipids and tryptic peptides from a grade II human astrocytoma tissue 
section. As indicated in the 2D conformation plot, phospholipids tend to have longer 
td values than peptides of the same m/z.
18 By exporting the peptide and the more 
abundant phospholipid signals separately into two different mass spectra (Figure 
1b), signals from each molecular class can be interrogated separately without signal 
interference from the other. This ability to simultaneously analyze and separate 
several biomolecular species provides a larger snapshot of the composition of tissue 
which MALDI IM-MS can provide without additional sample preparation or a 
significant increase in analysis time.   
 The fundamental separation process of classical drift cell IM-MS provides the 
capability to elucidate gas-phase structural information by determining an ion-neutral 
CCS. When the temperature, neutral gas pressure, length of the drift cell, mass of 
the drift gas, and mass and charge of the analyte are known (provided by MS), a 
CCS can be determined from the td of the analyte across the IM drift cell. While the 
physical principles behind the classical drift cell IM separation are well studied and 
understood, the underlying theories behind a recently developed IM termed 
traveling-wave (t-wave) are currently being developed.19, 20 However, methods to 
obtain t-wave IM-MS CCS values are currently being developed including the work 
presented here.20-27 IM-MS CCS values have been reported for a variety of analytes 
including:  carbohydrates,28-30 peptide secondary structure,31-33 phospholipids,17, 23, 26 
protein tertiary structure,34, 35 and even non-covalent protein complexes.21, 36, 37 
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Analyte CCS values for biomolecular species are typically used in conjunction with in 
silico structural information.32, 33, 38-40 The structural information from gas-phase CCS 
values has provided information ranging from the branching configurations of 
carbohydrates to protein structural changes under differing conditions and is 
obtainable with limited sample amounts and where species contain several distinct 
conformations. Further, the structural information elucidated by IM-MS provides 
complementary data to other technologies which provide atomic structural resolution 
but require large amounts of sample or are only able to measure species with static 
molecular structures.  
  
Direct Analysis of Tissue Sections by Mass Spectrometry 
 
Sample preparation. Typically, a flash-frozen tissue sample is prepared for MALDI 
MS analysis by preparing a 12 μm thick section using a cryostat (~-18°C) and thaw-
mounting it onto a MALDI target. Targets may be gold-coated, stainless steel, ITO 
(indium-tin oxide) coated glass slides, or microscope slides.8, 41 While gold-coated 
targets offer better light contrast for observation of specific tissue features, ITO-
coated glass slides (Delta-Technologies, Stillwater, MN) and microscope slides 
provide the capability of histologically staining the tissue section before or after MS 
analysis.42 In contrast to microscope slides, ITO-coated glass slides have an 
electrically conductive surface compatible with the high voltage sources used in 
MALDI TOFMS instruments.2 Depending on the experiment, tissue sections may be 
washed or dipped into solvents prior to matrix application to improve the signal for 
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proteins and peptides by the removal of salts and lipids.8, 43  Washing is not typically 
recommended for MS analysis of lipids or pharmaceutical compounds as these may 
be delocalized.  
 Traditionally, the MALDI matrix characteristically consists of a small organic 
acid which co-crystallizes with analytes extracted from the sample or tissue section. 
Matrix compounds exhibit high absorption by electronic excitation at the wavelength 
of the pulsed laser (ultraviolet, UV), while most molecules are non-absorbing at 
these wavelengths.44 After laser ablation, analytes are desorbed and ionized when 
thermal energy is transferred from the matrix compound to the analyte.44, 45 The 
subsequent ions are then analyzed by MS. Common matrixes used for the analysis 
of peptides, lipids, and small molecules are 2, 5-dihydroxybenzoic acid (DHB) and α-
cyano-4-hydroxycinnamic acid (CHCA) while sinapinic acid (SA) is most often used 
for protein analysis.3, 8 An organic solvent such as acetonitrile or methanol is 
typically used for extraction of analytes from tissue sections prior to matrix co-
crystallization, but some success has been achieved using dry matrix applications.46, 
47 
 Matrix application may be performed by a variety of strategies depending on 
the experimental goal. When the desire is to acquire spectra from specific cells or 
groups of cells (profiling-mode MS analysis), matrix can be applied in a low-density 
array to the tissue section by manually hand-spotting using a pipette or in a high-
throughput fashion by automatic reagent spotters (Figure 2, left).41 Manually 
spotting matrix onto the tissue is typically performed by applying µL amounts of 
matrix to form a spot approximately 1 mm in diameter while robotic spotters produce  
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matrix spots approximately 100-200 μm in diameter. Matrix application by automatic 
reagent spotters such as the Portrait 630 (Labcyte, Sunnyvale, CA) or the 
piezoelectric-based chemical ink-jet printer (ChIP-1000, Shimadzu Co., Kyoto, 
Japan) can also be performed in a histology-directed manner.48-52 For histology-
directed strategies, the tissue section for MS analysis or a serial section is stained 
and features of interest are specifically selected for MS analysis. This approach is 
typically performed during high-throughput MALDI MS studies where knowledge on 
the molecular differences between certain cell types within a tissue section is 
desired. 
 When the experimental desire is to acquire spectra from all regions of the 
tissue (imaging-mode MS analysis, commonly referred to as imaging mass 
spectrometry, IMS), matrix application can be performed by automatic reagent 
spotters in either a high-density array or by spraying matrix in a homogenous coating 
(Figure 2, right). Spraying the matrix solution directly onto the section to achieve a 
homogenous coating can be performed either manually using a TLC nebulizer or by 
commercial automatic sprayers such as the ImagePrep (Bruker Daltonics, Bremen, 
Germany) or other spray devices.53, 54 With a homogenous coating of matrix across 
the tissue section, the spatial resolution of the image is dependent on the laser spot 
size on the target, but one must take care to prevent delocalization of analytes 
caused by over-wetting the tissue section. Alternatively, matrix can be applied in a 
high density array (approximately 100 – 250 µm center to center spacing) by 
automatic reagent spotters. By applying the matrix in a high-density array, analytes 
are contained within the diameter of the matrix spot, ensuring limited analyte 
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delocalization. Further, sublimation or a dry coating of matrix can also be used to 
produce a layer of small crystals (less than 20 µm) across the tissue section and has 
been found to be especially applicable for MALDI MS analysis of lipids.46, 47After 
matrix application, the specific x-y coordinates of the matrix spots are then 
transferred to the MS. Mass spectra are then systematically acquired at the specified 
coordinates across a tissue section and the intensities of m/z values are 
subsequently used to reconstruct 2D ion density maps. 
 
Mass spectrometric analysis. MALDI MS is typically performed using pulsed UV 
lasers (N2, 337 nm; or frequency-tripled Nd:YAG, 355 nm) to raster at predefined x-y 
coordinates across the tissue section. MALDI lasers typically have spot sizes 
focused between ~25 to 150 µm and are operated between 20 to 1000 Hz.41 
Research is actively being performed to increase both laser frequency and lateral 
resolution. The newer frequency-tripled Nd:YLF (349 nm) UV lasers have a high 
repetition rate laser (up to 20 kHz) but typically perform at repetition rates of 5 kHz or 
below.55 High lateral resolution has been achieved by decreasing the laser 
irradiation spot to the average size of most mammalian cells (~ 10 µm) using optics 
with a coaxial illumination grid-less two-stage ion source and N2 laser.
56 This 
particular configuration was able to image proteins up to m/z 27,000 directly from a 
12 µm thick mouse epididymis tissue section at a ~ 7 µm spatial resolution.56 
Additionally, higher lateral resolution can be achieved by oversampling the laser 
where a smaller laser raster increment is used than the laser beam width.57 This 
10 
 
approach was successfully applied to image neuropeptides from Aplysia nerve cells 
(~80 to 100 µm) at a lateral resolution of 25 μm.  
 Several MS analyzers have been coupled to MALDI and routinely utilized for 
direct tissue analysis. For protein analysis, a linear time-of-flight (TOF) instrument is 
typically used where ions are accelerated through a field-free region of the TOFMS 
analyzer and are separated based on the equation:   
 
        
 
   
 
where T is time-of-flight, q is charge, m is mass, and k is a proportionality constant 
related to instrument operating potentials and dimensions. Ions of the same charge 
have the same kinetic energy and are thus separated based on their differing 
velocities which are dependent on their m/z. Ions of the same charge but smaller 
masses will travel at higher velocities and have shorter flight times than ions of 
larger masses. By using a set of known standards, these flight times can be 
accurately converted to precise m/z values through instrument calibration.  
 For the analysis of lower molecular weight species (less than m/z 6,000) such 
as peptides, phospholipids, and pharmaceutical compounds, higher mass resolution 
is desired and a reflectron or “ion mirror” can be used to achieve this.58 Additional 
TOFMS platforms such as orthogonal TOFMS (oTOFMS) can also be utilized for the 
analysis of low molecular weight species.59 An oTOFMS is positioned 
perpendicularly to the ionization source decoupling ionization and MS detection. An 
oTOFMS analyzer is commonly used subsequently to both quadrupole (a mass 
11 
 
filter) and IM. Typically, a multi-channel plate detector and a time-to-digital converter 
are utilized for ion detection on MALDI TOFMS platforms.  
 MALDI has also been coupled with other MS platforms including Fourier 
transform ion cyclotron resonance (FTICR) which provides higher mass resolution 
and accuracy than any other mass analysis technique.60, 61 Alternatively, molecular 
specificity may also be achieved by performing tandem MS or MS/MS by monitoring 
the transition from the original compound to the subsequent fragments. MALDI 
MS/MS analysis is typically utilized for identification purposes such as determining a 
peptide sequence or the structure of a pharmaceutical compound and is applicable 
for monitoring selected species directly from complex samples such as tissue 
sections. MALDI MS/MS of species directly from tissue sections has been performed 
on multiple platforms including: MALDI LTQ,6, 62 MALDI TOF/TOFMS,52 and MALDI 
QTOFMS.3  
  
MALDI ion mobility - mass spectrometry. For this work, analysis of tissue 
sections by MALDI IM-MS is reported on two platforms:  a MALDI drift cell IM-
TOFMS (Ionwerks, Inc., Houston, TX) and a t-wave IM-TOFMS (SYNAPT HDMS 
System, Waters Corporation, Manchester, UK). Schematics of these instruments are 
illustrated in Figure 3 and Figure 4, respectively.63, 64 The MALDI drift cell IM-
TOFMS utilizes a solid-state Nd:YLF (349 nm) high repetition rate laser routinely 
operated between 300 and 1000 Hz. Ions are injected into a drift cell about 15 cm in 
length that is maintained at 3 to 5 Torr He to produce a mobility resolution (ΔT/T) of 
approximately 30 to 50. MALDI is performed at the same pressure as the drift cell  
12 
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which offers collisional cooling of the ions. After the mobility separation, ions are 
directed through a differentially pumped region and analyzed by oTOFMS. The 
arrival time of an ion to the pulser of the oTOFMS analyzer is referred to as the 
arrival time distribution (ATD) which is the time an analyte travels from ionization to 
the pulser. The ATD is different than td which is the amount of time it takes an ion to 
travel though the drift cell only (time ions spent outside of IM is not subtracted). The 
mobility separation is completed on a µs-ms time scale and flight times in the TOF 
analyzer are on the order of µs so several mass spectra are recorded for each 
mobility separation. Due to the large data file size (from both the ion mobility drift cell 
and TOF analyzer) for each pixel, imaging MALDI IM-MS is generally performed by 
selecting a 4 µs drift time window for each imaging experiment. This approach 
increases the TOF duty cycle while maintaining a manageable data file size 
(typically less than 2 Gb). Therefore, mass spectra are only recorded from a region 
of the lipid or peptide trend-line providing biomolecular class specific images devoid 
of isobaric chemical noise. The 2D conformation space displaying the ATD or CCS 
is plotted as a function of m/z (Figure 1a) and images are reconstructed using 
customized software.65, 66 
 In the case of the MALDI t-wave IM-TOFMS, (Figure 4) after ionization, 
analytes are guided to a quadrupole where they can be transmitted or isolated for 
subsequent tandem MS. After exiting the quadrupole, ions are accumulated in a trap 
region prior to being released into a t-wave IM device (ms drift times) and 
sequentially analyzed by oTOFMS. For this particular platform, 200 mass spectra 
are collected per each IM event. Further, all td and m/z data are collected for the  
14 
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entire image creating files greater than 20 Gb for 10 mm2 sections imaged with a 
200 µm spatial resolution. Class specific and simultaneous analysis of all 
biomolecular species are performed by collecting all data from the IM and TOFMS 
dimensions during analysis and selecting signals of interest from the resulting 2D 
conformation plot for spectra or image reconstruction. Spectra are visualized using 
MassLynx software (Waters Corp.) and images are converted to the Analyze file 
format using MALDI Imaging Converter Software (Waters Corp.) and visualized 
using Biomap (Novartis, Basel, CH). 
 The t-wave technology consists of a series of stacked ring electrodes in which 
a continuous wave of dc pulses on adjacent electrodes guides ions through N2 gas 
(~10-1 Torr in the cell).64 Two parameters that influence the mobility resolution are 
the dc wave height (typically 7.5 to 12 V but can be set as high as 25 V) and the dc 
wave velocity (between 300-600 V). The traveling-waves of dc pulses provide a 
higher sensitivity due to the radial refocusing of ions, but t-wave IM typically has a 
lower mobility resolution (approximately 5 to 15) than drift cell IM instruments. The 
difference in mobility resolution is compensated to an extent by the high resolution of 
the reflectron oTOFMS analyzer that can either be operated in V mode (~15 000 R) 
or W mode (~20 000 R).  
 
Applications of Tissue Analysis by Mass Spectrometry 
 
Protein analysis by MALDI MS. The ability to characterize the molecular 
components of specific cell populations within tissue sections and between healthy 
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and diseased tissue samples has made MS a valuable tool for both proteomic and 
lipidomic based research.67-69 The high-throughput nature of MALDI MS provides the 
potential to analyze large numbers of tissue samples rapidly in a spatial resolved 
manner. For example, MALDI MS provides the capability to analyze specific 
subpopulations of different grades and malignancies of tumor cells within a 
heterogeneous sample providing a spatially resolved molecular snapshot.8 This 
technology has been widely applied to probe the molecular composition of multiple 
diseased tissues including human gliomas, breast tumors, and non-small cell lung 
tumors along with normal tissue samples to further understand underlying molecular 
mechanisms.5, 6, 8, 9, 49 
 Currently, the major method of diagnosis, prognosis, and predicting effective 
therapies for human diseases, specifically cancer, is histological/pathological 
evaluation.  While pathology is critical for timely disease evaluation and prognosis, 
additional molecular information is expected to greatly enhance individual patient 
care. Of specific clinical interest are the determination of biomarkers for reliable early 
disease detection, therapy response prediction, and elucidation of the specific 
molecular events found in and adjacent to diseased tissues. Figure 5 illustrates 
MALDI MS analysis of a human renal cell carcinoma biopsy, showing the presence 
of tumor and adjacent noncancerous tissue.41 For protein analysis by MALDI MS, 
matrix was automatically applied by a robotic spotter every 250 µm in rows across 
the tumor margin. The resulting spectra (m/z range 4 to 20 kDa) were combined and 
displayed as a heat map with spatial and m/z information clearly displaying multiple 
intensity differences between the cancerous area (Figure 5, displayed at the top of  
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the optical section) and the adjacent noncancerous tissue (Figure 5, bottom of 
the optical section). The molecular patterns that were observed within the 
cancerous tissue itself are consistent with the heterogeneous cellular content of the 
tumor. Spectra acquired from within the noncancerous area (Figure 5, spectra 5 
and 12) contain some features similar to those in spectra acquired from the 
cancerous area (Figure 5, traces 22-29). It is interesting to speculate that these 
molecular similarities between the noncancerous tissue and the cancerous tissue 
represent the beginning of cellular transformation in cells near the tumor and may 
indeed be early signs of precancerous growth.41 
 
Analysis of peptides by MALDI MS. In classical proteomic studies, protein 
identification schemes consist of tissue homogenization and high performance liquid 
chromatography (HPLC) separation followed by enzymatic cleavage prior to peptide 
sequencing by MS/MS and database searching.5, 8 Generally, this method requires 
an extensive amount of time and relatively large amounts of tissue. Recently, 
methods have been optimized to perform protease digestion directly onto the tissue 
section without the need for tissue homogenization.52, 70 In situ enzymatic digestion 
is performed by spotting trypsin directly onto the tissue section prior to matrix 
application and directly analyzing the resulting tryptic peptides (m/z 500 to 4000) by 
MALDI MS. This strategy provides the ability to rapidly map and sequence tryptic 
peptides directly from the tissue section and search protein databases to identify 
proteins with high confidence. The direct analysis of tryptic peptides also enables the 
ability to analyze higher molecular weight or membrane bound proteins typically not 
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desorbed and ionized using routine sample preparation methods. Several studies 
using in situ tryptic digestion of fresh-frozen tissue sections has demonstrated the 
localization and identification of neurogranin, mulitple isoforms of rat brain myelin 
basic protein, and the 71 kDa synapsin I protein.52 Additionally, this protocol can be 
adapted to use other in situ chemistries directly on tissue sections.  
 MALDI IM-MS can further enhance proteomic analysis of biological tissue 
sections by separating peptides by their structure in addition to m/z. For instance, 
the analysis of a single matrix spot from in situ enzymatic digested tissue sections 
produces thousands of distinct peaks with a signal to noise greater than three.52 
Here, 2D separations by IM-MS could provide the ability to analyze lower abundant 
peptides normally not detected due to larger overlapping signals. Previous work has 
also shown evidence that 2D separations provided by MALDI IM-MS can be used to 
target phosphopeptides which typically have smaller td values than unmodified 
peptides of the same m/z and negatively deviate from the peptide trend-line.71, 72 
Here, IM could provide an additional rapid gas-phase fractionation step prior to MS 
analysis to separate unmodified peptides from phosphopeptides, typically found in 
low-abundance, directly from tissue sections. 
 
Phospholipid analysis by MALDI MS. Lipidomics is a rapidly growing research 
field in part because of the role of lipids in normal biological and disease processes. 
Phospholipids are a diverse group of molecules which are the structural components 
of cell membranes and are involved in signaling pathways, protein sorting, and 
energy storage. Phospholipids also serve as precursors for ceramides, eicosanoids, 
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inositol phosphates, and lysophosphatidic acids, which in turn activates various 
cellular responses including proliferation, angiogenesis, and apoptosis.73 Altered 
levels in lipid composition are found in many pathological conditions such as:  
Alzheimer‟s disease (AD), Down syndrome, diabetes, and cancer as well as many 
other diseases.74-76 Additionally, altered levels in phospholipid composition have 
been evaluated by MALDI MS during normal biological process. For instance, 
Figure 6 depicts differences in phospholipid distributions as mouse uterine cells 
undergo molecular changes between day 4 and day 8 of pregnancy. The two main 
groups of phospholipids observed by MALDI MS in positive mode are 
phosphatidylcholine (PC) and sphingomyelin (SM). At the top of each column in 
Figure 6, the phospholipid species is labeled where the first number corresponds to 
the total number of carbon atoms in the two fatty acid chains, and the second 
number represents the number of double bonds in both fatty acid chains. Below in 
parenthesis, the number of carbon atoms and degree of saturation are displayed for 
the sn1 and sn2 fatty acid chains, respectively. SM species contain a sphingosine 
backbone in place of the sn1 fatty acid. In mice, prior to embryo attachment (occurs 
during day 4 of pregnancy), the luminal epithelial cells (Figure 6, middle of the day  
4 optical image) show a substantial increase in intensity of SM 16:0 and PC  
species with 18:1, 18:2, and 20:4 as their unsaturated fatty acid chain. Conversely, 
PC (16:0/16:0) shows a relatively higher intensity in all cell types except for the 
luminal epithelial cells and an altered localization pattern compared with the other 
phospholipids during days 4 through 8. On day 8 of pregnancy, many of the  
 
21 
 
 
22 
 
phospholipids show higher intensity either in the mesometrial pole (PC species 
containing 18:1 as the sn2 fatty acid) or antimesometrial pole (PC species containing  
18:2, 20:4 or 22:6 as the polyunsaturated fatty acid). These results provide new 
insights into the distribution of phospholipids during pregnancy and illustrate the 
benefits of utilizing a non-targeted technology which provides a molecular identity.  
 MALDI IM-MS can enhance phospholipid analysis by distinguishing between 
different species such as SM and PC. SM species have been shown to have longer 
td values than PC species of the same m/z.
17, 26, 77 Additionally, some evidence has 
indicated that phospholipids of different degrees of unsaturation and with different 
cations can be resolved on different trend-lines.23, 77 This provides not only additional 
separation to decrease signal overlap, but also provide tools for molecular 
identification which complement MS/MS. 
  
Analysis of pharmaceutical compounds by MALDI MS. MALDI MS has been 
shown to be an effective analytical tool for the analysis of exogenous pharmaceutical 
compounds directly from tissue sections. Mapping the localization of drugs and their 
metabolites to determine pharmacokinetic (PK) information or the absorption, 
distribution, metabolism, and excretion (ADME) of a compound is essential in order 
to obtain FDA approval. Current pharmaceutical imaging technologies, such as 
whole body autoradiography (WBA) or fluorescence imaging, detect the distribution 
of a label throughout dosed animals, thus it is not known if the detected signal arises 
from the original drug molecule, a metabolite, or any other compound resulting from 
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the transfer of the label. Therefore, further analysis is required to obtain additional 
information on the nature of the monitored species.78  
 MALDI MS provides information on the spatial distribution and molecular 
identity of drugs and drug metabolites in tissue sections at therapeutic doses.3, 7, 79 
Typically MS/MS or a single reaction monitoring (SRM) strategy is employed for 
MALDI MS analysis of pharmaceutical compounds due to the high abundance of 
endogenous analytes and matrix interference found below m/z 1000. SRM is 
performed by monitoring the intensity of the transition of a precursor ion to a major 
fragment.7 To date, several studies have analyzed the distribution of drugs and their 
metabolites by MALDI MS/MS in tissue sections and even whole body animal 
sections.3, 4, 7, 80 For example, Figure 7 shows the distribution of the antipsychotic 
olanzapine (m/z 313  256, Figure 7b) and its two first-pass metabolites, N-
desmethyl-olanzapine (m/z 299  256, Figure 7c) and 2-hydroxymethyl-olazapine 
(m/z 329  272, Figure 7d) throughout a whole rat tissue section two hours post-
dose.3 MALDI MS/MS clearly shows that the olanzapine signal is localized in the 
target organs:  brain and spinal cord. Importantly, little to none of the N-desmethyl 
and 2-hydroxymethod metabolites were detected in the brain and spinal cord. The 
MS data obtained from this study provided a system wide evaluation of each 
compound in a single individual animal section and is in agreement with previous PK  
studies.81 This is in contrast to WBA data which revealed that radioactivity 
associated with isotopically labeled olanzapine was distributed throughout the tissue 
of an entire rat, but provided no information of the molecular identity of the detected  
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compound.81 Thus, WBA alone could not determine whether olanzapine or 
metabolites were localizing to the targeted organs. 
 The analysis of pharmaceutical compounds directly from dosed tissue 
sections by MALDI IM-MS provides several advantages including the ability to 
separate pharmaceutical compounds from endogenous chemical noise prior to 
fragmentation and the ability to perform simultaneous fragmentation of all species 
following IM separation.82-84 When fragmentation occurs after IM separation, the td of 
fragment ions correlates with the td of the parent molecule and are separated in 
conformation space from other species of the same m/z.82, 83 Therefore, each 
analyte of interest is able to be fragmented and analyzed in a single imaging 
experiment. For example, Figure 8a displays a 2D conformation plot of the non-
selective beta blocker, propranolol (m/z 260) with fragmentation occurring after IM 
separation. The fragment ions of m/z 218, 182, 157, 116 all have the same td as the 
original molecule and are also resolved from a matrix derived analyte.16 MALDI IM-
MS/MS of drugs has been utilized to image the distribution of vinblastine (VBL), an 
anti-tumor agent, throughout whole rat tissue sections (Figure 8b).84 Here, 
separation of VBL from an interfering isobaric phospholipid was required to obtain 
the correct pharmaceutical distribution. VBL (m/z 811) is fragmented to m/z 751, 
542, 524, 719, 649, and 691, and the reconstructed images for each fragment 
(except for m/z 751) indicate that the distribution of VBL is localized to the liver, renal 
cortex, and in the tissues surrounding the GI tract, in agreement with WBA imaging. 
Conversely, the distribution of the parent ion at m/z 811 and the SRM transition of 
m/z 811 → 751 indicated VBL is additionally localized to the kidney (Figure 8b and  
26 
 
 
27 
 
c). When dosed tissue sections were analyzed by MALDI IM-MS/MS, the distribution 
of VBL for the SRM transition m/z 811→ 751 at the td correlating to VBL was not 
localized to the kidney but has a distribution more similar with the other transitions of 
VBL and results from MALDI IM-MS analysis (Figure 8d and e). The localization to 
the kidney area when analyzed without utilizing IM separation was determined to 
arise from an interfering isobaric endogenous phospholipid which also forms a 
fragment of m/z 751.  
 The limitation for simultaneous fragmentation of all species by MALDI IM-
MS/MS is the ability to resolve the molecules of interest. Thus, this strategy is 
especially applicable in cases to monitor structurally different metabolites. Resolving 
metabolites which only differ from the original drug molecule by a hydroxyl or methyl 
group by IM may be difficult, but strategies utilizing more polar drift gases such as 
CO2 provide additional selectivity and have shown promise for the analysis of drugs 
and other small molecules.85, 86  
 
Summary and Research Objectives 
 MALDI MS provides the spatial distribution, relative abundance, and 
molecular identity of numerous analytes directly from tissue sections.7, 67, 87 Due to 
the complex nature of these samples, additional fractionation is needed to increase 
the specificity of MALDI MS for analytes of interest from other components in the 
sample. We hypothesize that rapid post-ionization gas-phase separations by IM can 
be utilized to structurally separate isobaric species, separate different classes of 
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biomolecules, obtain gas-phase structural information, and simultaneously fragment 
all species directly from thin tissue sections prior to MS analysis.  
 The objective of this study was to evaluate the utility of IM to provide rapid (µs 
- ms) separations prior to MS analysis of tissue sections. In Chapter II, MALDI IM-
MS is evaluated as a rapid post-ionization separation tool for the analysis of tissue 
sections. Imaging of nominally isobaric species (peptides and phospholipids) is 
presented as well as the selective and simultaneous analysis of peptides and 
phospholipids directly from tissue sections. The benefits of utilizing MALDI IM-MS as 
a separation tool for the analysis phospholipids and peptides directly from tissue 
sections are explored. In Chapter III, methods are developed to determine low-
resolution structural information in the form of a CCS of phospholipids and peptides 
directly from tissue sections by MALDI t-wave IM-MS. Further, the use of MALDI IM-
MS for the selectivity of peptides containing posttranslational modifications (PTMs) 
based on their gas-phase packing efficiency is evaluated. In Chapter IV, the utility of 
MALDI IM-MS for the analysis of small molecules (less than m/z 500), such as 
pharmaceutical compounds is assessed. While it has been previously shown that 
larger pharmaceutical compounds (m/z 811) can be separated from an isobaric 
phospholipid species, the use of MALDI IM-MS/MS to resolve and simultaneously 
analyze small pharmaceutical compounds and their metabolites has yet to be 
researched. In particular, the CCS of eighteen different pharmaceutical compounds 
including their metabolites are obtained to determine the ability of the current IM to 
resolve these species, as well as the utility of MALDI IM-MS/MS to simultaneously 
image four pharmaceutical compounds. In Chapter V, perspectives on the utility of 
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MALDI IM-MS for direct tissue analysis and insights into the future directions of this 
novel technology are provided.  
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CHAPTER II 
 
PROFILING AND IMAGING OF TISSUES BY MALDI  
ION MOBILITY – MASS SPECTROMETRY 
 
Abstract 
Direct tissue analysis by MALDI MS often results in complex and congested spectra 
which are difficult to interpret. Although MALDI MS is a powerful molecular profiling 
and imaging modality, it is clear that many low abundant species are not detected. 
Here, 2D separations were performed directly from tissue sections on the basis of 
MALDI IM-MS. IM-MS separates ions by both structure (apparent surface area) and 
m/z, which provides a rapid separation of isobaric, but structurally distinct analytes. 
The advantages of using MALDI IM-MS for the analysis of tissue sections are 
demonstrated by profiling human glioblastoma multiforme tissue sections and 
performing imaging of phospholipids and tryptic peptides directly from rat brain 
tissue sections.  
 
Introduction 
 MALDI MS of endogenous biological species (e.g. lipids, peptides, proteins, 
etc.) directly from tissue sections has demonstrated great utility in life science and 
medical research. In particular, IMS provides spatially resolved ion intensity maps 
corresponding to the intrinsic m/z of each intact molecular species anlayzed.1, 4, 41, 88 
IMS approaches have provided new opportunities in a wide variety of applications, 
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including the spatial determination of differential protein expression between disease 
and control tissue,89 characterization of tumor and adjacent non-tumor tissue,90 and 
mapping the localization of drug and metabolite distribution in targeted tissue or in 
the context of whole body animals.3, 7, 80 Nevertheless, there remain several 
considerable limitations in IMS analysis of tissue sections. Primary among these are 
the difficult peak assignments in the congested spectra due to the large number of 
endogenous analytes. The preponderance of ionized material may not correspond to 
analytes of interest which can result in high background signals (chemical noise). 
Moreover, in complex samples such as tissue sections, the identity or molecular 
class (i.e. lipid, peptide, etc.) from which chemical noise arises may be unknown 
and/or isobaric at masses corresponding to the desired analytes. This can result in 
erroneous and inaccurate conclusions on the distributions of analytes throughout 
tissue sections. Although MALDI MS/MS can often elucidate or validate the 
molecular identity of signals, only a limited number of analytes can be sequenced at 
a particular location before the sample is consumed.7 This is exacerbated as the 
IMS spatial resolution increases and the absolute amount of sample at each position 
decreases, providing further motivation for developing methodologies which provide 
higher data dimensionality without attenuation of the figures of merit obtained.  
 Here, we describe post-ionization 2D separations based on IM-MS to 
enhance the data dimensionality during the imaging process. Specifically, IM-MS 
provides 2D separations on the basis of molecular structure or apparent surface 
area and m/z in the IM and MS dimensions, respectively.11-14, 82 Previously, MALDI 
IM-MS was utilized for molecular profiling directly from rat brain tissue sections 
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which provided structural resolution of phospholipid and peptide species.91 Here, we 
demonstrate fully automated and high throughput profiling and imaging MALDI IM-
MS on two instrument platforms: MALDI drift cell IM-MS and the commercially 
available MALDI t-wave IM-MS. The advantages of utilizing MALDI IM-MS for tissue 
analysis is demonstrated by profiling experiments of human glioblastoma multiforme 
(GBM) tissue sections and selective and simultaneous imaging of phospholipids and 
peptides directly from rat brain tissue sections. The challenges associated with the 
additional separation dimension in MALDI MS applications are discussed.  
 
Results 
 The two MALDI instrument platforms used for this study (t-wave and drift cell 
IM-MS) provide IM resolving power of approximately 5-15 and 30-50 (t/t), 
respectively. An important design consideration for imaging MALDI IM-MS is the 
balance of keeping the IM separations sufficiently fast so that imaging data 
acquisition rates are not adversely affected while maintaining sufficient IM resolution. 
Although higher IM resolution can be achieved using longer drift cells with attendant 
higher separation voltages, this comes at the cost of longer IM separations. For the 
MALDI drift cell IM-MS platform (Figure 3), experimental conditions were selected 
where the IM separation is less than 600 μs and the 2D separation is completed 
prior to the next MALDI event at 1000 Hz. IM separations by MALDI t-wave IM-MS 
platform (Figure 4) are longer than the time between laser pulses (200 Hz UV laser, 
IM separations are between 10 to 15 ms), which is overcome by accumulating ions 
in the trap region prior to pulsing into the t-wave IM. Thus, on both platforms, the 
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addition of IM does not compromise data acquisition rates of contemporary MALDI 
MS experiments.  
 By adding a post-ionization structural separation with IM prior to mass 
analysis, a three-dimensional dataset is obtained at each x-y coordinate (pixel) 
interrogated during an imaging experiment. This is illustrated conceptually in Figure 
9. Although the data at each pixel location is three-dimensional (ATD or td, m/z, and 
signal intensity), 2D plots are typically reported with the signal intensity projected as 
false coloring. Representative data for MALDI drift cell IM-MS molecular profiling of 
human GBM tissue sections are reported in Figure 10. Ethanol washing is a 
common sample preparation procedure for the analysis of proteins and peptides by 
MALDI MS to remove salts and abundant phospholipids which can give rise to ion 
suppression effects.8 For both the not washed (Figure 10a) and washed GBM 
samples (Figure 10b), signals arising from isobaric phospholipids and peptides are 
baseline-resolved on the basis of the IM separation. The utility of ethanol washing to 
reduce ion suppression effects is also demonstrated by the observation of 
significantly higher peptide signals observed in the washed versus not washed 
sections. For comparison purposes, the mass spectra that would be observed in the 
absence of IM separation are illustrated in Figure 10.  
 
Molecular profiling of tissue sections. Lipid and peptide mass spectra are 
typically acquired separately using optimized sample preparation and MALDI MS 
acquisition methods for each biomolecule. By collecting both phospholipids and 
tryptic peptide signals simultaneously, proteomic and lipidomic information can be  
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acquired from the same laser pulse during a single MALDI MS experiment. Here, 
MALDI IM-MS was utilized to simultaneous analyze both of these biomolecular 
species from a single experiment in a histology-directed manner.   
 Histology-directed profiling by MALDI t-wave IM-TOFMS and MALDI TOFMS 
was performed on nine human GBM tissue samples. The work-flow followed for 
histology-directed profiling of phospholipids and tryptic peptides directly from tissue 
sections by MALDI t-wave IM-MS is outlined in Figure 11. For each sample of 
human GBM, two sections were prepared for MALDI MS analysis (Figure 11a) while 
a serial section was prepared for pathological interrogation of selected cells or areas 
of interest for MS analysis (Figure 11b). Marked GBM areas are then co-registered 
for matrix application and MS analysis. After MALDI t-wave IM-TOFMS analysis, 
phospholipids and peptide signals are exported separately to produce biomolecular 
specific spectra (Figure 11c-e) which are compared to phospholipid and tryptic 
peptide spectra collected by MALDI TOFMS using the optimal sample preparation 
for each biomolecular class. Samples were grouped based on their time of survival 
after diagnosis:  patients who survived less than one year after initial diagnosis and 
those which survived at least 1.5 years after diagnosis.  
 For phospholipid analysis, the signal intensity and quality between the two 
MS platforms are comparable (Figure 12a and c). From MALDI TOFMS 
phospholipid spectra, 189 peaks are detected while 98 peaks are detected when 
phospholipid signals are acquired simultaneously with peptide species by MALDI t-
wave IM-TOFMS. Of these phospholipid peaks, 71/98 are shared between the two 
MS platforms. The additional peaks detected by MALDI TOFMS were expected 
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since currently this platform is currently more sensitive than the MALDI t-wave IM-
TOFMS platform, but the additional peaks are not due to a higher mass resolution 
since both of these MALDI platforms provide mass resolutions on the order of 
10,000 – 15,000 in this mass range.  
 For tryptic peptide analysis, signal intensity between the two instrument 
platforms was comparable, but S/N was not. Spectra containing peptide signals 
acquired by MALDI t-wave IM-TOFMS had an overall decrease in S/N and detected 
peaks compared to spectra acquired by MALDI TOFMS (Figure 12b and d). While 
MALDI TOFMS detected 308 peaks, only 78 peaks were detected when tryptic 
peptides are analyzed in the presence of phospholipids.  Of these, 21/78 peaks were 
shared between spectra acquired by the two methods. The lower S/N, higher 
baseline, and decreased peaks detected is mainly due to the large amount of salt 
adducts and the formation of clusters in the reduced pressure ion source. When MS 
spectra are acquired from ethanol washed tissue sections, the S/N increases and 
more peptide signals are present (data not shown). While IM cannot prevent ion 
suppression, higher IM resolution and source vacuum may decrease suppression of 
peptide signals due to adducts and provide an increase in peptide sensitivity.  
 
Imaging of isobaric species. Imaging MALDI drift cell IM-MS of nominally isobaric 
peptide and phospholipid species which were deposited on a mouse liver tissue 
section is illustrated in Figure 13. Using an automated reagent spotter, the pattern of 
an „X‟ was deposited onto the tissue where each line was deposited with a peptide 
(RPPGFSP) standard or phosphatidylcholine extract (PCE) spiked into the DHB  
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matrix (Figure 13a). A representative 2D conformation plot for a mixture of these 
two species is shown in Figure 13b, where the peptide and an isobaric phospholipid 
(PC 34:2) are baseline resolved in the IM dimension with ATD peak maxima at 449 
and 504 μs, respectively. Selective ion intensity maps for the peptide and 
phospholipid are illustrated in Figure 13c, where in both cases the same m/z 
window (759–760) is interrogated, but at different ATD centered about the 
corresponding ATD peak maxima. Thus, although selective peptide and 
phospholipid images are obtained on the basis of the structural IM separation 
(Figure 13c, left and middle), the overlay ion intensity map (Figure 13c, right) is 
what would be obtained by MALDI MS-only imaging. This experiment was also 
repeated using MALDI t-wave IM-MS and similar results were obtained (data not 
shown). This is a significant result, since it illustrates the attenuation/rejection of 
chemical noise on the basis of structural separation. In this example, if the target 
molecule to image using MS was the peptide, then chemical noise (i.e. the isobaric 
phospholipid) would result in the erroneous image of „X‟ rather than the accurate 
image of „/‟.  
 
Selective imaging of endogenous phospholipids. Imaging MALDI drift cell IM-MS 
of endogenous phospholipids in a thin section of rat brain is illustrated in Figure 14. 
For registration, an optical image of a serial tissue section is shown in Figure 14a. 
Molecular profiling of an adjacent section by 2D IM-MS is shown in Figure 14b 
where nearly baseline resolved signals are observed for phospholipids and peptides 
obtained from brain gray matter. For imaging MALDI drift cell IM-MS, a 2D region  
42 
 
 
43 
 
corresponding to lipids, predominately PC species, at an IM ATD of 480 – 484 μs 
and a corresponding MS region of m/z 700–840 was selected. Figure 14c shows an 
integrated IM-MS image over this range, where lipid signals appear most prevalent 
in the gray matter and nearly absent in the corpus callosum or other white matter 
tracts. Qualitatively, these data are in good agreement with published IMS reports on 
phospholipid imaging of rat brain tissue sections.47, 92 Figures 14d and e display two 
representative extracted ion images from this dataset, demonstrating the 
heterogeneous spatial distribution of specific phospholipid species.   
 
Simultaneous imaging of endogenous phospholipids and tryptic peptides. 
Endogenous phospholipid and tryptic peptide species from a rat brain tissue section 
were simultaneously imaged by MALDI t-wave IM-MS. After imaging, signals along 
the phospholipid and peptide trend-lines were exported separately to generate their 
respective images. Tissue histology (Figure 15a) and known biology correlates with 
the distribution of phospholipid (Figure 15b) and peptide species (Figure 15d). For 
instance, SM species and myelin basic protein are typically distributed within the 
white matter such as the corpus callosum. Moreover, the spatial distribution of tryptic 
peptides from myelin basic protein isoform 2 correlate with the intact protein (Figure 
15c) and have higher intensities throughout the corpus callosum and striatum. This 
figure indicates that phospholipids and peptide species can be simultaneously 
imaged from the same tissue section (and laser pulse), and, by a post-ionization 
fractionation, their signals can be individually interrogated to specifically determine 
their spatial distribution. 
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Conclusions 
 IM-MS 2D separations provide several unique advantages over MS-only 
techniques. IM provides analyte separation proportional to apparent surface area, 
which can be used to separate ions on the basis of structure prior to m/z separation 
by MS analysis. Profiling of GBM tissue sections by MALDI t-wave IM-MS indicated 
that information on the phospholipid and peptide species may be obtained 
simultaneously and exported separately for biostatistical analysis. Even though 
MALDI TOFMS analysis detected more peaks with a higher S/N, global information 
from more than one biomolecular class may be desired. Further, selective and 
simultaneous imaging MALDI IM-MS was successfully demonstrated in a fully 
automated mode for the structural and m/z separation of analytes directly from 
tissue sections. Thus, in contrast with MALDI TOFMS, imaging MALDI IM-MS 
provides several unique advantages including:  (1) qualitative identification of the 
analyte molecular class, (2) separation/rejection of undesirable endogenous 
chemical noise, and (3) separation of isobaric species.  
 
Materials and Methods 
 
Materials. Sinapinic acid (SA), ammonium bicarbonate, -cyano-4-hydroxycinnamic 
acid (CHCA), 2-5 dihydroxybenzoic acid (DHB), ethanol (EtOH), and bovine trypsin 
were purchased from Sigma Chemical Co. (St. Louis, MO) and used without further 
purification. HPLC grade methanol (MeOH), acetonitrile (ACN), trifluoroacetic acid 
(TFA), reagent grade ethanol (EtOH), and glacial acetic acid were purchased from 
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Fisher Scientific (Pittsburgh, PA). Trypsin Gold was purchased from Promega 
(Madison, WI) and diluted in 50 mM acetic acid to obtain a final concentration of 0.5 
μg/μl for the stock solution. Human GBM (grade IV) brain tumors were obtained from 
the Molecular Neurosurgical Tissue Bank at the Vanderbilt University Medical 
Center. 
 
Sample preparation for tissue profiling by MALDI drift cell IM-MS. For 
demonstration of tissue profiling using MALDI drift cell IM-MS, fresh frozen GBM 
tissue sections were cut into 12 μm sections with a cryostat and thaw-mounted onto 
gold-plated MALDI targets. Sections were spotted with 40 mg/ml DHB in 70% MeOH 
and 0.1% TFA using the dried droplet method. For comparison purposes, tissue 
sections were either left not washed or washed with EtOH which has been 
previously described.8 Briefly, the washing step consisted of three 30 s washings at 
70, 70, and 95% EtOH, respectively. Tissues were analyzed by MALDI drift cell IM-
MS as described below. 
 
Sample preparation for histology-directed tissue profiling. For histology-
directed profiling of GBM by MALDI IM-MS, fresh frozen GBM tissue was cut into 12 
μm sections with a cryostat and thaw-mounted onto gold-coated MALDI targets. Two 
sections per tissue sample were prepared for MALDI t-wave IM-TOFMS analysis 
while one serial section was histologically stained by H&E for pathological 
evaluation. Additionally, two sections each were prepared for MALDI TOFMS 
analysis of phospholipids and tryptic peptide, along with serial sections for H&E 
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evaluation. GBM cells or areas of interest were marked from the H&E section (225 
µm diameter, slightly larger than the 200 µm matrix spot size). The marked H&E 
section was then co-registered with the section for MALDI MS analysis. Sections 
were prepared for phospholipid analysis by MALDI TOFMS by applying matrix (40 
mg/ml DHB in 50% MeOH and 0.1% TFA) using an automatic reagent multispotter 
(Portrait 630, Labcyte Inc., Sunnyvale,CA) over 11 iterations at 8 drops per iteration 
to give a total matrix spot volume of 10 nl. Coordinates of the matrix spots were then 
imported into MALDI TOFMS for automatic MS acquisition. 
 For tryptic peptide analysis by MALDI TOFMS, tissue sections were washed 
prior to matrix application with three 30 s washings of 70, 70, and 95% EtOH, 
respectively. Subsequently, trypsin (0.083 μg/μl in 100 mM ammonium bicarbonate 
pH 8) was applied by a Portrait 630. Briefly, trypsin was spotted onto the rat brain 
tissue sections over a series of 11 iterations by depositing 8 drops (100 pl per drop) 
per iteration in 3 min intervals to achieve a total spot volume of 8.8 nl. Digested 
spots appeared to dry completely between each successive spotting iteration. 
Trypsin spotting proceeded at room temperature (26 °C) over a period of 2 h, 
allowing ample time for digestion to occur. Following digestion, a solution consisting 
of 40 mg/ml of DHB in 50% MeOH and 0.1% TFA was spotted directly onto the 
tryptic spots over 11 iterations at 8 drops per iteration to give a total matrix spot 
volume of 10 nl. Coordinates of the matrix spots were then imported into MALDI 
TOFMS for automatic MS acquisition. 
 Sections were prepared for MALDI t-wave IM-MS analysis by applying trypsin 
as outlined above and, subsequently, matrix (15 mg/ml CHCA in 50% ACN and 
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0.1% TFA) using a Portrait 630 over a series of 20 iterations by depositing 6 drops 
(100 pl per drop) per iteration. No tissue washing was performed prior to trypsin and 
matrix deposition. Coordinates of the matrix spots were then imported into the 
MALDI t-wave IM-MS for automatic MS acquisition. 
 
Sample preparation for imaging MALDI drift cell IM-TOFMS. For demonstration 
purposes, imaging experiments were performed using 12 μm sections from CD1 
mouse liver thaw-mounted onto a gold-plated MALDI target and washed with EtOH 
as described above. A Portrait 630 was used to deposit 40 mg/ml DHB in 70% 
MeOH and 0.1% TFA spiked with either 1 mg/ml of the peptide RPPGFSP (Sigma) 
or 2 mg/ml PCE (Avanti). Matrix spots were deposited onto the section in an array 
with an average spot size of 125 μm and approximately 300 and 600 nmoles per 
spot for RPPGFSP and PCE, respectively and then imaged by MALDI drift cell IM-
MS in imaging mode as described below.  
 For imaging of endogenous phospholipids directly rat brain tissue sections, 
experiments were performed utilizing fresh frozen rat brain (Sprague–Dawley) which 
were sectioned into 12 μm coronal sections and thaw-mounted onto gold-plated 
MALDI targets. Sections (not washed) were spray-coated with 40 mg/ml DHB in 
70% MeOH and 0.1% TFA using a TLC nebulizer and then imaged by MALDI drift 
cell IM-MS in imaging mode as described below. 
  
Sample preparation for imaging MALDI t-wave IM-TOFMS. Sprague-Dawley 
adult rat brains were dissected, flash-frozen, and stored at -80°C until analysis. Rat 
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brain tissue was cut into 12 μm coronal sections using a cryostat and thaw-mounted 
onto microscope slides. Tissue sections were then placed in a desiccator for at least 
20 min. For simultaneous imaging of phospholipids and tryptic peptides, application 
of 300 µg bovine trypsin in 30 ml of 100 mM ammonium bicarbonate pH 8 was 
performed in a homogonous coating by an automatic sprayer (ImagePrep, Bruker 
Daltonics, Bremen, Germany). Subsequently, DHB (40 mg/ml in 70% MeOH and 
0.1% TFA) matrix was applied in a homogenous coating. After trypsin and matrix 
application, sections were imaged by MALDI t-wave IM-MS as described below.  
 
Profiling and imaging by MALDI drift cell IM-MS. The MALDI drift cell IM-MS 
instrument utilizes a solid-state frequency-tripled Nd:YLF (349 nm) high repetition 
rate MALDI laser (Explorer, Newport/Spectra-Physics Corp., Mountain View, CA). 
MALDI was performed at the pressure of the IM drift cell and at pulse repetition rates 
of 300 and 1000 Hz for profiling and imaging, respectively. Subsequent to MALDI 
ionization, the ions were injected into a 13.9 cm long IM drift cell, maintained at 3 to 
5 Torr He, which was operated at separation field strengths of 23 V cm-1 Torr-1 in all 
cases. As the ions elute from the IM drift cell, they are directed to the source of an 
oTOFMS with an effective ion flight path of 85 cm, operated in reflectron mode. 
Imaging was performed using custom stage motion and data acquisition control 
software (Ionwerks Inc., Houston, TX) at a spatial resolution of 200 μm. At each 
spatial position, data were acquired for 3 s, while the MALDI stage moved 
continuously in a programmed herring-bone (i.e. „V‟) pattern across each 200 μm 
location, resulting in 3000 laser shots/pixel. Data were interrogated utilizing custom 
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visualization software developed in the IDL programming environment (Ionwerks, 
Inc.). To illustrate complementary MS-only profiling spectra acquired in IMS, a 
MALDI TOFMS (Ultraflex III, Bruker Daltonics, Inc., Billirica, MA) was used. The 
latter was operated in reflectron mode with a Smartbeam frequency-tripled Nd:YAG 
(355 nm) laser operated at 200 Hz. Reported lipid identities were confirmed by 
MS/MS analysis, directly from tissue sections by MALDI TOF/TOFMS (Ultraflex III, 
Bruker Daltonics, Inc., Billirica, MA). In all cases the MALDI IM–TOFMS and MALDI 
TOFMS were operated in the positive ion mode. 
 
Histology-directed profiling by MALDI t-wave IM-MS. Histology-directed profiling 
of GBM tissue sections was performed by a MALDI t-wave IM-TOFMS (SYNAPT 
HDMS Waters Corporation, Manchester, UK) with MassLynx version 4.1. Spectra 
were acquired by automatically rastering the UV laser (150 µm laser spot size, 400 
laser shots) across each matrix spot. The wave height was linearly ramped between 
3 and 18 V with a wave velocity of 300 V and a drift gas pressure (N2) of (10
-1 Torr). 
After data acquisition, signals from the phospholipid and peptide trend-lines were 
selected and exported for spectral processing using DriftScope version 2.0. 
Exported signals from the phospholipid and peptide trend-lines were converted from 
the MassLynx format to a comma delimited file format using in house software for 
subsequent processing. 
 
Histology-directed profiling by MALDI TOFMS. MALDI TOFMS acquisition was 
performed automatically by an Ultraflextreme (Bruker Daltonics, Inc., Billirica, MA) 
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operated in reflectron mode with a Smartbeam frequency-tripled Nd :YAG (355 nm) 
laser operated at 1 kHz. The laser spot size is approximately 35 µm, and spectra 
were summed from 600 laser shots. After data acquisition, spectra were converted 
from the Bruker file format to a tab delimited file for visualization. 
 
Histology-directed profiling spectral processing. Multiple spectra from individual 
patients were averaged by ProTS-Marker (Biodesix Inc., Steamboat Springs, CO). 
The averaged spectrum from each patient was then arbitrarily grouped based on 
survival time by either less than 1 yr after diagnosis (n=4) or more than 1.5 yrs after 
diagnosis (n=6). Both spectra groups were imported into ClinPro Tools 2.2 (Bruker 
Daltonics) and baseline correction was achieved using a top hat algorithm with a 
10% minimal baseline width and the data normalized to TIC.  
 
Simultaneous imaging of phospholipids and peptides by MALDI t-wave IM-MS. 
Simultaneous imaging of phospholipids and tryptic peptides were performed by 
MALDI IM-TOFMS in positive ion mode. A digital image was imported into MALDI 
Imaging Pattern Creator (Waters Corp.) to create the raster pattern for the imaging 
experiment. Imaging was performed with a 150 µm spatial resolution with 400 laser 
shots per pixel. The wave height was linearly ramped between 3 and 18 V with a 
wave velocity of 300 V and a drift gas pressure (N2) of (10
-1 Torr).  After data 
acquisition, signals from the phospholipid and peptide trend-lines were selected and 
exported for image reconstruction separately using DriftScope version 2.0. Exported 
signals were converted into the Analyze file format using MALDI Imaging Converter 
52 
 
Software (Waters Corp.) with a 0.1 Da bin size and visualized using Biomap 
(Novartis, Basel, CH). Species were identified directly from tissue sections using 
accurate mass measurement from an FTICR (9.4 T Apex Qe, Bruker Daltonics, 
Billerica, MA) and by MS/MS using a MALDI SYNAPT HDMS in Q-TOF mode. 
MALDI MS/MS of phospholipids was performed using DHB matrix doped with 100 
mM LiCl.6, 93 To match peptide sequences to their respective intact proteins, 
sequences were submitted into a MASCOT (Matrix Science, Boston, MA) search 
engine and run against the NCBI database.  
 
Protein imaging by MALDI TOFMS. Protein imaging was performed from a serial 
rat brain tissue section by MALDI TOFMS (Autoflex II, Bruker Daltonics, Billerica, 
MA) equipped with a solid-state Smartbeam laser operating at 200 Hz. Imaging was 
performed at a 200 µm spatial resolution was used with a laser spot size of 
approximately 70 µm. Data was collected from 600 laser shots per pixel and 
converted into the Analyze file format and visualized using Biomap (Novartis, Basel, 
CH).  
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CHAPTER III 
 
STRUCTURAL CHARACTERIZATON OF PHOSPHOLIPIDS AND PEPTIDES 
DIRECTLY FROM TISSUE SECTIONS BY MALDI TRAVELING-WAVE 
 ION MOBILITY - MASS SPECTROMETRY 
 
Abstract 
IM-MS provides rapid 2D separations based on analyte apparent surface area or 
CCS and m/z, respectively. Recently, t-wave IM-MS was developed which uses 
electrodynamic rather than the electrostatic fields commonly utilized in drift cell IM-
MS instruments. The underlying theory for obtaining CCS data is well developed for 
drift cell IM-MS, while strategies for obtaining t-wave IM-MS CCS values remains an 
active area of research. In this report, methods were developed and validated to 
obtain phospholipids and peptides CCS values directly from tissue sections by 
MALDI t-wave IM-MS using MALDI drift cell IM-MS CCS calibrants. Importantly, the 
average percent difference between t-wave and drift cell IM-MS CCS measurements 
is minimized by calibrating with the same biomolecular class. Calibrating 
phospholipid t-wave IM-MS CCS values with peptide drift cell IM-MS CCS calibrants 
results in an average percent difference of approximately 7% between the same 
species measured by t-wave and drift cell IM-MS, while this improves to less than 
0.5% difference when phospholipid drift cell IM-MS CCS values are used for 
calibrating t-wave IM-MS data. A suite of MALDI t-wave IM-MS CCS values are 
reported for phospholipids and peptides which were determined directly from tissue, 
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i.e. without the need for tissue extraction and further purification steps. Additionally, 
MALDI t-wave IM-MS CCS values of peptides containing PTMs such as 
phosphorylation, levuglandin adduction, and farnesylation were obtained from both 
standards and tissue extracts. The possible advantages and strategies of utilizing 
MALDI t-wave IM-MS for added specificity for the analysis of peptides containing 
PTMs directly from complex samples are discussed. 
 
Introduction 
 IM-MS provides rapid (µs-ms) 2D gas-phase separations based on analyte 
apparent surface area or CCS in the mobility cell and m/z in the MS analyzer.14, 15, 94, 
95 By performing an IM separation prior to MS analysis, isobaric species can be 
resolved based on structure, and chemical noise can be separated from analytes of 
interest. These rapid 2D separations are especially applicable for the analysis of 
complex samples such as human plasma and thin mammalian tissue sections 
without additional sample preparation or a significant increase in analysis time.65, 66, 
93, 96, 97  
 IM-MS also provides qualitative information of biomolecular class based on 
preferences in the prevailing intramolecular folding forces which yields characteristic 
CCS versus m/z correlations for different classes of molecules.16, 17 For example, 
phospholipids typically have larger CCS values than peptides of the same m/z, and 
these two biomolecular classes are easily resolved when directly analyzing complex 
biological samples such as thin animal tissue sections.16, 17, 65, 66 While the majority 
of singly-charged gas-phase peptide ions adopt compact globular conformations, 
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some peptide ions exhibit an ordered structure such as helical content which has 
been shown to be stabilized by C-terminal acidic residues or other structures which 
are based largely on the solvation of charge sites on the peptide backbone amide 
groups.31, 33, 98 Thus, peptide CCS values are dependent on multiple factors 
including the amino acid sequence, peptide length, and the presence or absence of 
charged PTMs.31, 33, 71, 72, 98-101 The majority of CCS values of phosphopeptides fall 
below the predicted peptide trend-line and the utility of IM-MS as a selective screen 
for phosphopeptides has been described.25, 71, 72 The lower CCS values of 
phosphopeptides is thought to be the result of intramolecular interactions between 
basic side chains on the peptide and the negative charge carried on the 
phosphate.71, 72 
 In addition to a gas-phase separation tool, IM provides the capability to 
elucidate structural information on the basis of the ion-neutral CCS. While the 
physical principles behind classical drift cell IM-MS separations are well studied and 
understood, theories behind the commercially available t-wave IM are currently 
being developed.19, 20 Drift cell IM utilizes a static electric field to guide analytes 
through a neutral gas. At a given electrostatic field strength, the ion td is inversely 
proportional to the IM, which in turn is related to an absolute CCS which can be 
directly calculated. In contrast, t-wave IM separates ions using electrodynamic fields 
consisting of a series of stacked ring electrodes where a continuous wave of DC 
pulses guides ions through the chamber of neutral gas.64 Even though t-wave IM-MS 
is unable to measure an absolute CCS directly from a td, a t-wave IM-MS CCS can 
be obtained with calibrants of known drift cell IM-MS CCS. Several examples of t-
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wave IM-MS CCS values have been obtained for protein complexes,21, 102 
proteins,22, 103 and peptides25 using drift cell IM-MS CCS calibrants.    
 In this report, we explore obtaining peptide and phospholipid MALDI t-wave 
IM-MS CCS values directly from rat brain tissue sections. Methods were optimized 
and validated to use MALDI drift cell IM-MS CCS values as calibrants to obtain 
MALDI t-wave IM-MS CCS values. Previously, ESI and DESI ionization sources 
have been used to obtain t-wave IM-MS CCS values.21, 22, 25, 104 It has yet to be 
determined whether CCS values measured using ESI drift cell IM-MS can be 
successfully used as calibrants to obtain MALDI t-wave IM-MS CCS values, or if 
peptide CCS values can be used to calibrate phospholipid CCS values.63 Here, it is 
demonstrated that MALDI t-wave IM-MS CCS values are more accurate when 
MALDI drift cell IM-MS CCS calibrants are used than calibrants measured by ESI 
drift cell IM-MS. Additionally, it is demonstrated that phospholipid t-wave IM-MS CCS 
values are more accurate when calibrated using phospholipid CCS values than 
peptide CCS values. This indicates that to determine accurate t-wave IM-MS CCS 
values, calibrants should have similar CCS to m/z correlations (e.g. the same 
chemical class) instead of only similar CCS values and be measured using 
comparable ionization techniques.  
 The ability to measure the spatial distribution and relative amounts of proteins 
containing PTMs is important since the modified states of protein modifications may 
be altered in disease. PTMs may be dynamic or permanent, and can change the 
protein structure or function. Further, the presence of PTMs is not inherently able to 
be deduced based on genomic information alone and is typically determined by 
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proteomic studies. Besides using IM to separate and distinguish between different 
biomolecular classes, evidence has shown that IM may be used to distinguish and 
separate peptides and phosphopeptides.25, 71, 72 By using surface sampling ionization 
techniques such as MALDI, the 2D post-ionization separations provided by IM-MS 
can be used to separate phosphopeptides from more abundant unmodified peptides 
and analyze them directly from complex samples such as tissue sections. To 
evaluate the ability of MALDI t-wave IM-MS to separate and distinguish between 
unmodified and modified peptides, phosphopeptide CCS values were obtained and 
compared to unmodified tryptic peptides. Additionally, CCS values of peptides 
containing other biologically important PTMs which have not been previously 
analyzed by IM such as levuglandin (LG) adduction and farnesylation, were obtained 
and utilized to evaluate the ability of IM to separate and distinguish peptides 
containing these PTMs from unmodified peptides. 
 
Results 
 The aims of this study were to (1) develop and validate methods to utilize 
MALDI t-wave IM-MS to determine CCS values of phospholipids and peptides 
directly from animal tissue sections and (2) evaluate the utility of MALDI t-wave IM-
MS to separate low-abundant peptides containing PTMs from unmodified peptides 
directly from complex samples. MALDI t-wave IM-MS CCS values of PC species 
measured directly from tissue sections were compared using either reported values 
of tryptic peptides measured by both MALDI and ESI drift cell IM-MS (Table 1) or PC 
species measured by MALDI drift cell IM-MS (Table 2).99, 101 Additionally, obtaining 
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Table 1. 
 
BSA tryptic peptide MALDI drift cell IM-MS CCS external calibrants used for 
measuring t-wave IM-MS CCS values directly from tissue sections.  
peptide sequence 
m/z 
 [M + H]+ 
drift cell IM-MS CCS (Å2)c 
VASLRab   545.6 159 
CASIQKab 
AWSVARa 
649.3 
689.3 
182  
189 
SEIAHRa 712.3 188 
AEFVEVTKa 922.4 231 
YLYEIARa 927.4 244 
CCTESLVNRa 1024.4 252 
LVNELTEFAK 1163.6 279 
FKDLGEEHFKa 1249.6 290 
HPEYAVSVLLRa 1283.7 309 
HLVDEPQNLIK 1305.7 301 
RHPEYAVSVLLR 1439.8 321 
LGEYGFQNALIVR 1479.8 331 
DAFLGSFLYEYSR 1567.7 343 
KVPQVSTPTLVEVSR 1639.9 349 
RPCSALTPDETYVPK 1823.9 364 
HPYFYAPELLYYANK 1888.9 384 
RHPYFYAPELLYYANK 2045.0 397 
 
aPeptide CCS calibrants used to determine phospholipid t-wave IM-MS CCS values.  
CCS values of these peptides measured using ESI IM-MS99 were also used for 
comparison.  
bPeptide CCS calibrants used only for determining phospholipid CCS values and not 
tryptic peptide CCS values. 
cCCS values originally published by Tao et al. and measured by MALDI drift cell IM-
TOFMS.101 
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Table 2. 
 
Phospholipid MALDI drift cell IM-MS CCS internal calibrants used for 
measuring phospholipid t-wave IM-MS CCS values directly from tissue 
sections.   
species ion type m/z 
drift cell 
IM-MS  
CCS (Å2)a 
SM 18:0 [M + H]+ 731.6 221.1 
 [M + Na]+ 753.6 221.3 
PC 34:2   [M + H]+ 758.6 217.4 
 [M + Na]+ 780.6 218.9 
SM 20:0 [M + H]+ 759.7 229.8 
 [M + Na]+ 781.6 231.3 
PC 34:1 [M + H]+ 760.6 219.1 
 [M + Na]+ 782.6 221.7 
PC 36:2 [M + H]+ 786.6 222.6 
 [M + Na]+ 808.6 226.7 
PC 36:1 [M + H]+ 788.6 227.4 
 [M + Na]+ 810.6 228.1 
PC 42:0 [M + Na]+ 896.7 246.3 
 
aCCS values originally published by Fenn et al.17 
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accurate CCS values of tryptic peptides directly from tissue sections was validated 
by comparing to CCS values obtained from tryptic peptide standards measured by 
both MALDI drift cell and t-wave IM-MS. 
 
Collision cross section calibration of MALDI t-wave IM-MS. Since the 
fundamental theories behind t-wave IM separation have yet to be established, 
currently CCS values cannot be directly determined from measuring the td. Rather, a 
calibration curve of drift cell IM-MS CCS standards analyzed under the same 
conditions is used to obtain t-wave IM-MS CCS values of the analytes of interest. 
Here, reported MALDI drift cell IM-MS CCS values are used as calibrants to obtain 
MALDI t-wave IM-MS CCS values of species measured directly from rat brain tissue 
sections. A typical 2D td versus m/z conformation plot of data collected directly from 
a rat brain tissue section is displayed in Figure 16. Calibration curves for 
phospholipids (Figure17a) and BSA tryptic peptides (Figure 17b) were each 
measured at five different wave heights over two days (n=10). Both linear and power 
fits of the phospholipid calibration curve provided R2 values greater than 0.95. 
Importantly, the functional form of the CCS to m/z correlations do not change as the 
effective electrodynamic field is increased indicating IM separations are performed 
under low-field conditions. 
 
Analysis of phospholipids by MALDI t-wave IM-MS directly from tissue 
sections. Calibration strategies to obtain phospholipid t-wave IM-MS CCS values 
directly from tissue sections were developed and optimized. Specifically, two  
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calibration parameters were optimized:  (i) the effectiveness of using peptide MALDI 
derived drift cell CCS values for calibrating phospholipid MALDI derived t-wave CCS 
values and (ii) the utility of drift cell IM-MS CCS values obtained using ESI for 
calibrating t-wave IM-MS CCS values obtained using MALDI. All reported values are 
compared relative to absolute CCS values measured by MALDI drift cell IM-MS. 
When tryptic peptide values were used to calibrate endogenous PC species, the 
resulting t-wave IM-MS CCS values of PC species were systemically larger by an 
average of 6.4% and 1.2% when peptide drift cell IM-MS CCS values measured 
using MALDI and ESI were used, respectively (Figure 18). The correlation is 
significantly improved when phospholipid MALDI drift cell IM-MS CCS values were 
used to calibrate endogenous PC t-wave IM-MS CCS values with an average 
percent difference less than 0.5%. These results suggest that t-wave IM-MS CCS 
values can only be accurately measured using calibrants of the same biomolecular 
class. This observation supports the theoretical treatment of t-wave IM-MS CCS 
values by Shvartsburg et al., which indicates that t-wave IM-MS CCS values are 
most accurate when drift cell IM-MS CCS values of similar mobility are used.19 Thus, 
since biomolecules of different molecular classes exhibit distinct correlations of 
mobility versus m/z, this implies that drift cell IM-MS CCS values should be used that 
share similar CCS versus m/z correlations. The use of peptide drift cell IM-MS CCS 
values for calibrating lipids should be avoided.  
 The effect of the ion source used in the generation of drift cell IM-MS CCS 
values to calibrate t-wave data is also apparent in Figure 18. When either peptide or 
phospholipid data obtained using MALDI is used to calibrate MALDI t-wave IM-MS  
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CCS, the slopes of the correlation between t-wave and drift cell IM-MS CCS values 
are similar and near unity. The slopes for peptide and phospholipid calibrants are 
0.90 and 0.95, respectively. The primary difference between the two calibrations is a 
systematic offset to higher values using peptide data. When ESI values are used to 
calibrate for MALDI t-wave IM-MS CCS, the slope of the correlation is 0.79, where 
the net result is that larger deviations for t-wave IM-MS CCS values are observed at 
lower CCS and m/z values.  
The t-wave IM-MS CCS values of PC and SM species obtained directly from 
rat brain tissue sections and calibrated using phospholipid drift cell IM-MS CCS are 
shown in Figure 19. The specific molecular species identified and their t-wave IM-
MS CCS values are presented in Table 3. These results indicate that SM species 
typically have larger CCS values than PC species of the same m/z which is 
consistent with previous reports.17, 77  
 
Analysis of peptides by MALDI t-wave IM-MS directly from tissue sections. 
Determining the CCS values of tryptic peptides directly from tissue sections can 
potentially provide information on the peptide secondary structure and the presence 
of PTMs.25, 32, 71 Tryptic peptide CCS values from BSA over a mass range of 
approximately 500 to 2000 m/z were measured by MALDI drift cell IM-MS and used 
as external calibrants to obtain tryptic peptide MALDI t-wave IM-MS CCS values. 
The correlation between values obtained from the two IM platforms yields an R2 
greater than 0.98, and in all cases the percent difference is less than 4% (Figure 
20). The larger percent difference of peptide CCS values than lipid values is  
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Table 3. 
Phospholipid MALDI t-wave IM-MS CCS values obtained directly from tissue 
sections.  
class 
molecular 
species 
(C1 acyl chain/ 
C2 acyl chain) 
ion type m/z
a 
lithium induced 
MS/MS peaksb 
t-wave IM-
MS CCS 
(Å2)c 
SM 16:0 [M + H]+ 703.575  212.4 ± 3.6 
SM 18:0 [M + H]+ 731.606  220.5 ± 4.1 
  [M + Na]+ 753.588  221.3 ± 4.3 
  [M + K]+ 769.562  222.7 ± 4.8 
PC 32:0(16:0/16:0) [M + H]+ 734.569 
425, 657, 557, 
478, 552, 429 
215.3 ± 3.6 
  [M + Na]+ 756.551  217.4 ± 3.6 
  [M + K]+ 772.525  218.8 ± 4.3 
PC 34:4 [M + H]+ 754.537  217.6 ± 6.4 
PC 34:2 [M + H]+ 758.570  215.9 ± 4.0 
  [M + Na]+ 780.552  218.5 ± 4.2 
SM 20:0 [M + H]+ 759.638  223.8 ± 6.0 
  [M + Na]+ 781.619  226.5 ± 4.8 
  [M + K]+ 797.594  227.9 ± 5.7 
PC 34:1(16:0/18:1) [M + H]+ 760.585 
583, 451, 425, 
577, 504, 478 
218.4 ± 4.1 
  [M + K]+ 798.541  222.0 ± 4.7 
PC 36:3 [M + H]+ 784.584  224.6 ± 1.0 
  [M + K]+ 822.541  222.9 ± 1.6 
PC 36:2(18:1/18:1) [M + H]+ 786.600 609, 451 224.0 ± 4.3 
  [M + K]+ 824.557  226.2 ± 4.8 
PC 36:1(18:0/18:1) [M + H]+ 788.616 611, 451, 453 226.5 ± 4.7 
PC 36:4(16:0/20:4) [M + Na]+ 804.551 605, 473, 425 221.3 ± 1.9 
PC 38:6(16:0/22:6) [M + H]+ 806.570 629, 497, 425 220.6 ± 4.9 
  [M + K]+ 844.525  224.6 ± 4.8 
SM 22:0 [M + Na]+ 809.651  225.4 ± 4.2 
  [M + K]+ 825.625  228.2 ± 4.3 
SM 24:1 [M + H]+ 813.683  235.9 ± 6.6 
  [M + Na]+ 835.666  233.0 ± 4.8 
  [M + K]+ 851.640  240.5 ± 6.2 
SM 24:0 [M + H]+ 815.700  237.1 ± 5.7 
  [M + Na]+ 837.682  238.2 ± 6.2 
  [M + K]+ 853.656  241.2 ± 6.2 
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Table 3 (continued).  
 
class  
molecular 
species 
(C1 acyl chain/ 
C2 acyl chain) 
ion type m/z
a 
lithium induced 
MS/MS peaksb 
t-wave IM-
MS CCS 
(Å2)c 
PC 38:5 (18:0/20:5) [M + Na]+ 830.567 633, 473 222.2 ± 4.9 
PC 38:4(18:0/20:4) [M + Na]+ 832.584 633, 473, 453 228.5 ± 5.4 
  [M + K]+ 848.556  230.0 ± 5.0 
PC 42:1 [M + H]+ 872.711  248.0 ± 6.9 
  [M + K]+ 910.664  249.2 ± 7.3 
PC 42:0 [M + Na]+ 896.709  244.6 ± 5.7 
 
aData acquired by MALDI FTICR mass spectrometer. 
bFragment ions are arranged with the highest intensity ion (left) to lowest intensity 
ion in the MS/MS spectra (decimal values not included). 
cT-wave IM-MS CCS values are reported as the average of 10 replicate 
measurements using phospholipids MALDI drift cell IM-MS CCS values as internal 
calibrants (Table 2). 
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expected because the residuals to the peptide correlation are larger than that for the 
lipid correlation (Figure 17) and the calibration is performed over a wider range of 
m/z values, from ~500 to 2000 m/z and ~700 to 900 m/z for peptides and lipids, 
respectively. The calibration curves displayed in Figure 17 for these BSA tryptic 
peptide values were used to estimate the CCS of tryptic peptides directly from rat 
brain tissue sections (Figure 21, Table 4). Note that peptide t-wave IM-MS CCS 
values are only reported for those m/z values that contain only one peak when 
analyzed by MALDI FTICR, i.e. no peaks with concomitant nominally isobaric 
species were used. For reference, the endogenous phospholipid CCS values 
reported in Figure 19 are displayed which have larger CCS values than peptides of 
the same m/z which correlates with previous reports.16, 17  
 
Validation of peptide MALDI t-wave IM-MS CCS values. Tryptic peptide t-wave 
IM-MS CCS values obtained directly from tissue sections were compared to the 
same tryptic peptide CCS values obtained from in solution enzymatic digests of 
purified proteins and measured by both MALDI t-wave and drift cell IM-MS (Figure 
22, Table 5). CCS values obtained by MALDI t-wave IM-MS of in solution tryptic 
digests and tissue sections were similar (less than 2.5 % difference in all cases), and 
CCS values obtained between MALDI t-wave and drift cell IM-MS also had a high 
correlation with the highest percentage difference between the two techniques being 
less than 3.5%. These results indicate that tryptic peptide t-wave IM-MS CCS values 
can be obtained directly from thin tissue sections and other complex samples when 
appropriate drift cell IM-MS CCS calibrants are used.   
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Table 4. 
 
Assignment of tryptic peptide sequences and reported MALDI t-wave IM-MS 
CCS values measured directly from tissue sections.   
protein 
observed 
[M + H]
 +a
 
[M + H]
 +
calc 
 
ppm 
peptide sequence
b
 
t-wave IM-
MS CCS 
(Å
2
)
c
 
actin 1198.70 1198.706 -5.0 AVFPSIVGRPR 282.0 ± 2.2 
 1515.74 1515.7497 -6.4 IWHHTFYNELR 323.9 ± 2.8 
myelin  709.34 709.3422 -3.1 FSWGGR 193.9 ± 2.4 
basic 726.40 726.4051 -7.0 HGFLPR 203.4 ± 2.2 
protein 1131.57 1131.5798 -8.6 TTHYGSLPQK 267.4 ± 2.0 
 1336.63 1336.6319 -1.4 YLATASTMDHAR 296.3 ± 2.5 
 1339.70 1339.7082 -6.1 HRDTGILDSIGR 288.8 ± 1.9 
 1460.71 1460.7174 -5.0 TQDENPVVHFFK 310.2 ± 1.7 
 1800.84 1800.8458 -3.2 FSWGAEGQKPGFGYGGR 348.2 ± 2.8 
neurofilament  1265.65 1265.6563 -4.9 MALDIEIAAYR 294.7 ± 5.4 
protein 1296.70 1296.5682 -6.3 NMQNAEEWFK 291.6 ± 2.1 
tubulin, alpha 1701.90 1701.9063 -3.7 AVFVDLEPTVIDEVR 356.1 ± 1.7 
 1807.87 1807.8834 -7.4 AVCMLSNTTAIAEAWAR 385.7 ± 2.2 
 2006.89 2007.8936 -1.7 TIGGGDDSFNTFFSETGAGK 386.9 ± 3.1 
tubulin, beta 971.49 971.4984 -8.6 TAVCDIPPR 241.5 ± 1.5 
 1039.59 1039.594 -3.8 YLTVAAVFR 276.3 ± 1.5 
 1053.60 1053.6097 -9.2 YLTVAAIFR 277.7 ± 1.7 
 1077.53 1077.5328 -2.5 IREEYPDR 252.5 ± 2.2 
 1143.63 1143.6348 -4.1 LAVNMVPFPR 275.0 ± 2.5 
 1229.59 1229.5988 -7.1 ISEQFTAMFR 283.1 ± 1.7 
 1258.68 1258.6908 -8.5 FPGQLNADLRK 287.9 ± 1.9 
 1271.72 1271.7298 -7.7 KLAVNMVPFPR 293.6 ± 1.8 
 1601.81 1601.8209 -6.8 AVLVDLEPGTMDSVR 333.0 ± 2.4 
 1615.83 1615.8365 -4.0 AILVDLEPGTMDSVR 336.2 ± 2.7 
 1620.83 1620.8361 -3.7 LHFFMPGFAPLTSR 345.9 ± 2.2 
 
aData acquired by MALDI FTICR mass spectrometer.  
bMALDI MS/MS analysis of tryptic peptides directly from tissue sections acquired by 
MALDI Q-TOFMS.  
cT-wave IM-MS CCS values are reported as the average of 10 replicate 
measurements using BSA tryptic peptide drift cell IM-MS CCS values as external 
calibrants (Table 1). 
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Table 5. 
 
Tryptic peptide CCS values obtained from standards using MALDI drift cell 
and t-wave IM-MS.  
mammalian 
species 
protein peptide sequence m/z 
drift cell IM-
MS 
CCS (Å
2
)
 a
 
t-wave IM-
MS 
CCS (Å
2
)
 b
 
mouse myelin basic protein  FSWGGR 709.3 193.7 ± 2.8 193.9 ± 2.3 
  HGFLRP 726.4 204.7 ± 3.1 203.4 ± 2.2 
  YLATASTMDHAR 1336.6 289.5 ± 9.5 296.4 ± 2.5 
  HRDTGILDSIGR 1339.7 283.1 ± 8.0 288.9 ± 2.0 
  TQDENPVVHFFK 1460.7 305.5 ± 8.0 310.3 ± 1.8 
bovine myelin basic protein  HGFLRP 726.4 205.0 ± 2.3 203.4 ± 2.2 
  HRDTGILDSIGR 1339.7 286.1 ± 8.1 288.9 ± 2.0 
bovine actin AVFPSIVGRPR 1198.7 279.5 ± 6.8 282.0 ± 2.3 
  IWHHTFYNELR 1515.9 320.9 ± 7.7 323.9 ± 2.9 
 
aDrift cell IM-MS CCS values are reported as the average of 10 replicate 
measurements. 
bT-wave IM-MS CCS values are reported as the average of 10 replicate 
measurements using external BSA tryptic peptide drift cell IM-MS CCS values as 
calibrants (Table 1). 
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Analysis of phosphopeptides by MALDI t-wave IM-MS. The td or gas-phase CCS 
values of tryptic peptides can provide information on the presence or absence of 
PTMs. For instance, negative deviations from the predicated peptide trend-line 
indicate PTMs such as phosphorylation may be present.25, 71, 72 Phosphopeptides 
may have the same CCS value or a smaller CCS value to the unmodified peptide, 
and the additional mass of the phosphate group (80 Da) shifts the peptide in 
conformation space away from the unmodified peptide trend-line. For example, 
Figure 23 illustrates that the CCS value of the tryptic phosphopeptide 
RPFFPFHSPSR from the B-crystallin protein is the same as the unmodified form, 
but is still separated from the unmodified trend-line by -2.4%. From a recent study 
where the CCS values of over 600 peptides were measured by MALDI drift cell IM-
MS, the majority of peptide CCS values (~ 80%) were within ± 7.3% of the predicted 
peptide trend-line.16, 101 Further of the peptides measured, 70% (mostly tryptic 
peptides) were positively deviated from the peptide trend-line. Thus, since 
phosphopeptide CCS values typically fall below the peptide trend-line, 
phoshopeptides can be separated by IM from greater than 70% of the unmodified 
tryptic peptides prior to MS analysis.  
 To evaluate the ability of MALDI t-wave IM-MS to distinguish and separate 
phosphopeptides and unmodified peptides, phosphopeptide MALDI t-wave IM-MS 
CCS values were obtained directly from a protein digest of bovine -casein and β-
casein proteins (Figure 24, Table 6). Phosphopeptide MALDI t-wave IM-MS CCS 
values were smaller than unmodified peptides of the same m/z, and were separated 
from unmodified peptides even with a relatively low IM resolving power (~10 – 15 R).  
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The five singly phosphorylated peptides had CCS values which deviated from the 
unmodified peptide trend-line between -1.1 to -7.3%. The peptide 
FQpSEEQQQTEDELQDK has a high deviation from the peptide trend-line, but the 
CCS was +1% different from the unmodified form of the peptide. Therefore, the large 
difference is due to the compact structure of the unmodified peptide and not 
necessarily due to the addition of the phosphate group. The two tetraphosphorylated 
peptides displayed the largest percent deviations in CCS values from the predicted 
peptide trend-line of -7.7 and -11.0%. Notice that in all cases for CCS values 
reported in Table 6, the CCS values of the phosphopeptides are less than ± 3% 
different than the unmodified peptide, but the addition of 80 Da shifts the modified 
peptide away from the unmodified trend-line. 
 To evaluate the utility of MALDI t-wave IM-MS to separate phosphopeptides 
directly from complex samples, CCS values of -crystallin tryptic phosphopeptides 
were measured directly from a bovine lens tissue extract (Figure 25, Table 7). The 
three tryptic phosphopeptides detected and identified had CCS values below the 
unmodified peptide trend-line between -1.2 and -2.4%. This indicates that 
phosphopeptides are able to be analyzed directly from complex samples and tryptic 
phosphopeptides are able to be separated from greater than 70% of unmodified 
peptides prior to MS analysis.  
 
Analysis of levuglandin adducted peptides by MALDI t-wave IM-MS. LGs are - 
ketoaldehydes derived from prostaglandin H2 (PGH2), which is reportedly involved in 
biological processes such as cancer, inflammation, and AD.105, 106 In aqueous  
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solutions, PGH2 rapidly undergoes rearrangement to form LGs. Several LG forms 
have been characterized including: lactam, anhydrolactam, pyrrole, anhydropyrrole, 
and hydroxylactam (Figure 26).107-109 The -ketoaldehyde structure confers a high 
degree of reactivity which readily forms covalent adducts with amine groups on 
proteins by Paal-Knoor condensation.  
 To investigate the possible consequences of protein modification by LG 
adducts, analytical methods are required to analyze these low abundant species 
directly from complex samples. Here, we evaluate the use of MALDI t-wave IM-MS 
to separate LG adducted peptides from unmodified peptides by their difference in 
CCS and m/z. Unlike the negatively charged phosphate group, LG have carbon 
chains similar to fatty acid tails. It was hypothesized that these fatty acid-like chains 
would shift the peptide in conformation space above the unmodified peptide trend-
line. In fact, each of the five LG adducts shifted the peptide in conformation space 
above the peptide trend-line between 1.6 and 6.1% (Figure 27, Table 8).  In every 
case the change in CCS between the unmodified form and the adducted peptide is 
greater than 16%, but the addition change in m/z of ~300 shifts the adducted peptide 
in conformation space closer to the unmodified peptide trend-line. Additionally, there 
is a smaller shift in conformation space as peptide mass increases, indicating that 
MALDI IM-MS provides more selectivity for smaller adducted peptides (less than m/z 
1000). 
 
Analysis of farnesylated peptides by MALDI t-wave IM-MS. Farnesylation is a 
covalent modification which occurs on cysteines near the protein C-terminus with a  
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Table 8. 
 
Change in t-wave IM-MS CCS values of peptides due to levuglandin adduction.   
peptide 
sequence
a
 
LG adduct m/z 
t-wave IM-
MS CCS 
(Å
2
)
b
 
 in CCS 
(% difference)
c
 
% difference from 
peptide trend-line
d
 
lgLALDVLF no PTM 791 216.9 ± 2.3 n/a +1.1 
 anhydropyrrole 1089 278.9 ± 2.2 +22.2 +6.0 
 anhydrolactam 1105 281.2 ± 2.0 +22.8 +5.8 
 pyrrole 1107 279.2 ± 2.3 +22.3 +5.1 
 lactam 1123 284. 3 ± 2.1 +23.7 +5.9 
 hydroxylactam 1139 287.8 ± 1.8 +24.6 +6.1 
lgVISAVISF no PTM 836 220.0 ± 2.1  n/a -0.7 
 anhydropyrrole 1134 284.5 ± 2.3 +22.7 +5.4 
 anhydrolactam 1150 286.1 ± 1.5 +23.1 +5.0 
 pyrrole 1152 285.7 ± 2.0 +23.0 +4.7 
 lactam 1168 287.7 ± 2.6 +23.6 +4.5 
 hydroxylactam 1184 291.3 ± 3.3 +24.5 +4.8 
PPLISIEKlgK no PTM 1024 260.6 ± 1.1 n/a +3.4 
 anhydropyrrole 1322 313.1 ± 2.6 +16.8 +4.4 
 anhydrolactam 1338 316.2 ± 3.6 +17.6 +4.5 
 pyrrole 1340 317.2 ± 3.6 +17.8 +4.7 
 lactam 1356 319.2 ± 4.2 +18.4 +4.5 
 hydroxylactam 1372 319.6 ± 2.7 +18.4 +3.8 
lgWSITQAIEY no PTM 1110 259.2 ± 2.0 n/a -2.4 
 anhydropyrrole 1408 322.4 ± 2.6 +19.6 +2.9 
 anhydrolactam 1424 323.8 ± 2.4 +19.9 +2.5 
 pyrrole 1426 317.5 ± 3.3 +18.4 +0.5 
 lactam 1442 324.2 ± 2.0 +20.0 +1.8 
 hydroxylactam 1458 326.3 ± 3.0 +20.6 +1.6 
 
aAmino acid or n-terminus modified by levuglandin is marked by “lg”.  
bT-wave IM-MS CCS values are reported as the average of 10 replicate 
measurements using BSA tryptic peptide drift cell IM-MS CCS values as external 
calibrants (Table 1). 
cThe percent difference in CCS values between unmodified and modified peptide. 
dThe percent difference in CCS value from the calculated peptide trend-line from this 
experiment. 
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hydrophobic carbon chain. The addition of farnesyl groups has been shown to target 
signaling proteins such as H-Ras, n-Ras, and K-Ras, to the lipid bilayer.110, 111 To 
evaluate MALDI t-wave IM-MS as a method to investigate the degree of 
farnesylation of peptides in complex samples such as tissue sections, the CCS 
values of several farnesylated peptide standards were measured by MALDI t-wave 
IM-MS and compared to the unmodified peptides. Since the farnesyl group is similar 
in structure to lipid fatty acid tails (as are LGs), it was hypothesized that farnesylation 
will shift peptides in conformation space above the peptide trend-line. As shown in 
Figure 28 and reported in Table 9, farnesylation does shift peptides above the 
peptide trend-line between 1.8 to 8%. Farnesylated peptides showed a change in 
CCS between 11.5 to 25.9% which is similar to LG adduction, but since farnesylation 
only adds 204 Da to the peptide, the percent deviation away from the unmodified 
peptide trend-line is greater. 
 
Conclusions 
 Phospholipid and tryptic peptide CCS values were determined by MALDI t-
wave IM-MS directly from tissue sections. These results indicate that t-wave IM-MS 
values must be calibrated using CCS values measured by drift cell IM-MS for the 
same biomolecular class and by using the same type of ionization source to obtain 
accurate results. Although presently t-wave IM-MS CCS values can only be obtained 
using drift cell IM-MS CCS values as calibrants, the commercial availability of the t-
wave technology makes it a desirable platform for performing gas-phase structural 
studies. Through proper calibration this provides a high-throughput structural  
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Table 9. 
 
Change in t-wave IM-MS CCS values of peptides due to farnesylation.   
peptide 
sequence
a
 
m/z  
t-wave IM-
MS CCS 
(Å
2
)
b
 
 in CCS 
(% difference)
c
 
% difference from 
peptide trend-line
d
 
GRGDSPfC 895 236.8  ± 1.8 +22.2 +5.4 
HfCKFWW 1110 277.8 ±  1.8 +17.8 +7.4 
fCDPGYIGSR 1171 287.2 ± 2.2 +14.8 +7.2 
fCQDSETRTFY 1453 323.1 ± 3.3 +12.8 +4.0 
TMRKPRfCGNPDVAN 1763 364.3 ± 1.9 +11.5 +1.8 
     
 
aAmino acid which is modified by farnesylation is marked by “f”.  
bT-wave IM-MS CCS values are reported as the average of 10 replicate 
measurements using BSA tryptic peptide drift cell IM-MS CCS values as external 
calibrants (Table 1). 
cThe percent difference in CCS values between unmodified and modified peptide. 
dThe percent difference in CCS value from the calculated peptide trend-line from this 
experiment. 
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analysis tool for sampling directly from complex samples such as tissue extracts and 
thin tissue sections.  
 The utility of MALDI t-wave IM-MS was evaluated to separate peptides 
containing PTMs such as phosphorylation, LG adduction, and farnesylation from 
unmodified peptides. Phosphopeptides negatively deviate from the peptide trend-
line, and phosphopeptides which contain multiple sites of phosphorylation had larger 
percent deviations. While the change in t-wave IM-MS CCS between individual 
phosphorylated and unmodified peptides was not significant, the addition of 80 Da 
shifts the modified peptide away from the unmodified trend-line. Further, 
phosphopeptides were able to be analyzed directly from complex samples and 
tryptic phosphopeptides are able to be separated from greater than 70% of 
unmodified tryptic peptides prior to MS analysis.  
 LG adduction and farnesylation shifted peptides in IM-MS conformation space 
between 1.6 to 8% above the unmodified peptide trend-line. The peptide structural 
change is hypothesized to be due to the addition of the uncharged carbon chain(s). 
While IM may not have sufficient resolution and specificity to separate LG adducted 
and farnesylated peptides from all unmodified peptides directly from complex 
biological samples, recent studies have shown pepsin digested peptides fall below 
the peptide trend-line.101 Pepsin preferentially cleaves at hydrophobic aromatic 
residues which may provide insight into why pepsin peptides tend to be more 
compact. Thus, when analyzing LG adducted and farnesylated peptides, pepsin may 
be the ideal enzyme for protein digestion since the resultant peptides will be shifted 
away from the modified peptides of interest.  
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Materials and Methods 
 
Materials. Bovine and mouse myelin basic protein (MBP), bovine actin, bovine 
serum albumin (BSA), -casein, β-casein, dephosphorylated -casein, 
dephosphorylated β-casein, buckminsterfullerene (C60), ammonium bicarbonate, 2-5 
dihydroxybenzoic acid (DHB), dithiothreitol (DTT), iodoacetamide (IOA), and farnesyl 
bromide were purchased from Sigma Chemical Co. (St. Louis, MO) and used 
without further purification. HPLC grade methanol (MeOH), trifluoroacetic acid (TFA), 
reagent grade ethanol (EtOH), and glacial acetic acid were purchased from Fisher 
Scientific (Pittsburgh, PA). Bradykinin was purchased from American Peptide 
(Sunnyvale, CA), and trypsin gold was purchased from Promega (Madison, WI). 
MARCKS peptide standard was purchased from AnaSpec (San Jose, CA). The 
peptide standards, HCKFWW, GRGDSPC, CQDSETRTFY, and 
TMRKPRCGNPDVAN were purchased from Bachem (Torrence, CA). LG was 
synthesized by the Oates Laboratory as described previously.112 
 
Sample preparation. Brains from adult Sprague-Dawley rats were dissected, flash-
frozen, and stored at -80°C until analysis. Rat brain tissue was cut into 12 μm 
coronal sections using a cryostat and thaw-mounted onto gold-coated MALDI 
targets. The targets were then placed in a desiccator for at least 20 min. To prepare 
rat brain tissue sections for phospholipids analysis, 500 nl of 40 mg/ml DHB in 50% 
MeOH and 0.1% TFA was hand-spotted onto the tissue section three consecutive 
times allowing 5 min between iterations. To prepare rat brain tissue sections for 
91 
 
tryptic peptide analysis, a series of EtOH/H2O wash steps as described by Aerni et al 
were performed.48 Directly after washing the tissue sections were dried and stored in 
a vacuum desiccator until application of trypsin solution and matrix which were 
applied using a procedure described by Groseclose et al.52 Briefly, trypsin was 
diluted in 200 μl of 50 mM acetic acid to obtain a final concentration of 0.5 μg/μl for 
the stock solution. A 40 μl aliquot of this stock solution was activated by adding 200 
μl of 100 mM ammonium bicarbonate to reach a final trypsin concentration of 0.083 
μg/μl at a pH of 8. Selected areas of the tissue sections were spotted three 
consecutive times with 500 nl of a 0.083 μg/μl trypsin solution using a micropipette, 
with each spot being allowed to dry between trypsin solution applications. After 
drying, three drops of 500 nl DHB in 50% MeOH and 0.1% TFA were deposited at 
the same positions, allowing each spot to dry before the application of consecutive 
drops.  
 
Obtaining MALDI t-wave IM-MS CCS values. The CCS values of phospholipid and 
peptide species were obtained using a MALDI IM-TOFMS (SYNAPT HDMS Waters 
Corporation, Manchester, UK) with MassLynx version 4.1 and calibrated using 
previously published CCS values measured by a linear potential gradient drift cell 
IM-MS with either a MALDI or ESI ion source.17, 99, 101 The td of phospholipids and 
tryptic peptides was measured with a mobility pressure of 0.34 Torr N2 using five 
different linear wave voltages (wave heights) to ensure that separations were 
preformed under the low-field limit. To determine the t-wave IM-MS CCS of 
phospholipids, spectra were collected with wave heights of 7.5 to 9.5V in 0.5V steps 
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while wave heights between 10 to 12 V in 0.5V steps were used to acquire spectra 
of tryptic peptides. Multiple methods to calibrate CCS values using t-wave IM-MS td 
values in reference to drift cell IM-MS calibrants have been reported.21, 104 For this 
study, a slightly modified procedure reported by Williams et. al. was used.104 In 
contrast with using a linear regression for calibrating normalized CCS versus 
effective td, a power curve was used. Briefly, the td and CCS values of calibrants 
measured by drift cell IM-MS were normalized to charge state (z) and the square 
root of the reduced mass (µ). The resulting effective drift time (td‟) was plotted 
against the normalized drift cell IM-MS CCS and fitted to a power curve in the form 
of y=axb. T-wave IM-MS CCS values are then calculated using the formula:  
 
           
      
 
   
 
To determine the t-wave IM-MS CCS values of phospholipids directly from tissue 
sections, either reported drift cell IM-MS CCS values of BSA tryptic peptides ranging 
from m/z 545 to 1305, or SM and PC species from m/z 731 to 896 were used.17, 99, 
101 Calibration of phospholipids was performed using endogenous PC and SM 
internal calibrants measured directly from tissue sections, while BSA peptide drift 
cell IM-MS CCS values were used as external calibrants.  Furthermore, the effects 
of calibrating MALDI t-wave IM-MS CCS values using drift cell IM-MS CCS values 
measured by both ESI and MALDI were compared. To calibrate t-wave IM-MS CCS 
values of tryptic peptides directly from tissue sections, reported drift cell IM-MS CCS 
values of BSA tryptic peptides ranging from m/z 689 to 2045 were used.101   
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Phospholipid identification. Species were identified directly from tissue sections 
using accurate mass measurement acquired with a MALDI FTICR (9.4 T Apex Qe, 
Bruker Daltonics, Billerica, MA) and by performing tandem MS using MALDI IM-CID-
TOFMS equipped with an 8 kHz quadrupole with a parent ion window of 3 Da.  
Tandem MS of phospholipids was performed using DHB matrix doped with 100 mM 
LiCl providing fragmentation of the sn1 and sn2 fatty acid tails which has been 
described elsewhere.93 We report only t-wave IM-MS CCS values of phospholipid 
species with no overlapping peaks in spectra obtained by MALDI FTICR so multiple 
isobaric species from tissue sections are not measured and reported with a single 
CCS value. 
 
Tryptic peptide sequencing. An accurate mass measurement was obtained of 
tryptic peptides by MALDI FTICR, and peptide sequencing was performed directly 
from tissue sections by MS/MS using a MALDI Q-TOFMS. To match peptide 
sequences to their respective intact proteins, the MS/MS generated spectra were 
submitted into a MASCOT (Matrix Science, Boston, MS) search engine and run 
against the NCBI database. The MS/MS spectrum search was performed with a 
peptide tolerance of ± 0.3 Da and a fragment tolerance of ± 0.5 Da. The search 
criteria included up to three missed cleavages and variable modifications including 
lysine acetylation, N-terminus acetylation, C-terminus amidation, and methionine 
oxidation. Stringent criteria for reported peptide t-wave IM-MS CCS values include:  
complete sequence coverage by tandem MS, no isobaric species observed by 
MALDI FTICR, and multiple peptides must be identified from a single protein.   
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Peptide standards. Bovine MBP, mouse MBP, and bovine actin, -casein, β-
casein, dephosphorylated  -casein, and dephosphorylated  β-casein were each 
dissolved in 100 mM ammonium bicarbonate to a final concentration of 1 mg/ml. 
DTT was added to a final concentration of 2 mM, and the samples were incubated at 
50°C for 15 min. After cooling to RT, IOA was added to a final concentration of 20 
mM, and the samples were incubated in the dark at room temperature for 15 min. 
Trypsin was added to a final concentration of 83 ng/µl, and the samples were 
incubated overnight at 37°C. To stop the reaction, TFA was added until an acidic pH 
was reached. Before MS analysis, protein digests were desalted and purified by C18 
reverse-phase “Zip-Tip” pipette tips (Millipore Corp., Billerica, MA) following the 
manufacturer‟s instructions. The peptide samples were then co-crystallized with 40 
mg/ml of DHB in 50:50 MeOH:H2O and 0.1% TFA on a stainless steel MALDI target 
and analyzed by both MALDI drift cell and t-wave IM-MS.  
 
MALDI drift cell IM-MS.  For validation of peptide t-wave IM-MS CCS values, a 
MALDI drift cell IM-TOFMS similar to those previously described was used to 
measure tryptic peptide CCS values for comparison.14 Briefly, MALDI is performed 
by a solid-state frequency-tripled Nd:YLF (349 nm) MALDI laser (Explorer, 
Newport/Spectra-Physics Corp., Mountain View, CA). After ionization, analyte ions 
are introduced into a 13.9 cm ion mobility drift cell maintained at a pressure of ca. 
3.8 Torr He and at RT (~298 K). Ions are subsequently analyzed by m/z in an 
oTOFMS. Internal calibration of the MS was performed using C60. The 2D IM-MS 
spectra were acquired and processed using custom software developed in the IDL 
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programming environment (Ionwerks, Inc.). The ion-neutral CCS (Ω) was calculated 
by determining the td of the ion packet across the IM drift cell maintained at low-field 
conditions. The td of an ion through the IM drift cell depends on the temperature (T) 
and pressure (p) of the neutral drift gas, ion charge and shape, and the strength of 
the applied electric field (E, ~20 – 30 V cm-1 Torr-1). All MALDI drift cell IM-MS 
measurements were performed using five electrostatic field strengths to estimate t0, 
the time ions reside in the instrument outside of the drift cell, i.e. tmeasured- t0 = td.
113, 114 
Drift cell IM-MS CCS values were calculated using: 
 
  
        
  
  
       
 
 
 
  
 
 
  
 
      
 
   
 
 
      
 
  
 
 
where e is the elementary charge, kb is Boltzmann‟s constant, L is the length of the 
drift cell, z is the charge state of the ion, N0 is the drift gas number density at STP, 
and mi and mn are the masses of the ion and the neutral drift gas, respectively.
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Levuglandin adduction of peptides. LG adduction was performed in collaboration 
with Almary Chacon and the Oates Laboratory at Vanderbilt University.  Briefly, 
peptide standards were incubated with 5 molar equivalents of synthetic LG to obtain 
the following LG adducted peptides: lgVISAVISF, lgWSITQAIEY, lgLALDVLF, 
PGlgKAW, GGGGlgKGGR, and TPRRIlgKAIIVTVW, along with the unmodified 
versions of these peptides. Determining MALDI t-wave IM-MS CCS values of the 
unmodified and LG adducted peptides was performed as described for tryptic 
peptides above. 
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Farnesylation of peptides. Farnesylation of peptide standards has been previously 
described.116 Briefly, peptide standards (2 mg/ml) were incubated with Zn(OAc)2  
H2O in DMF/1-butanol/0.10% aqueous TFA (2:1:1, v/v/v) with 8 mg/ml of farnesyl 
bromide. Determining MALDI t-wave IM-MS CCS values of the unmodified and 
farnesylated peptides was performed as described for tryptic peptides above. 
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CHAPTER IV 
 
STRUCTURAL SEPARATIONS OF PHARMACEUTICAL COMPOUNDS  
BY MALDI ION MOBILITY - MASS SPECTROMETRY 
 
Abstract 
IMS is able to determine the relative amount and spatial distribution of exogenous 
pharmaceutical compounds throughout dosed tissue sections at therapeutic doses. 
Since MS provides a molecular identity, labeled drug compounds are not required. 
Typically, for small molecule imaging, SRM is performed separately on each analyte 
of interest due to the high abundance of endogenous analytes and matrix 
interference found below m/z 500. We hypothesize the addition of a structural gas-
phase IM separation will enable the ability to perform fragmentation of all species 
simultaneously increasing the number of small molecules capable of being imaged 
without an additional sample preparation or an increase in analysis time. In this 
report, the ability of current MALDI IM-MS instrumentation to structurally separate 
small molecules was evaluated. Further, MALDI IM-MS/MS was utilized to image 
four small molecules spotted onto a tissue section in a td and fragment m/z specific 
manner.   
 
Introduction 
 IMS is able to analyze exogenous pharmaceutical compounds directly from 
therapeutically dosed tissue sections. In contrast to other imaging methods such as 
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WBA, MS provides a molecular identity and thus a labeled compound is not 
required.3, 7, 78  To date, several studies have analyzed the distribution of drugs and 
metabolites by MALDI IMS in tissue sections and even whole body animal sections.3, 
4, 7, 80 Typically, imaging is performed by an SRM strategy for small molecule 
analysis due to the high abundance of endogenous analytes and matrix interference 
found below m/z 1000. Imaging is thus performed in a targeted fashion by selecting 
a single SRM transition to moniter corresponding to a parent or metabolite species 
at a time. As the number of molecules of interest increase, either additional analysis 
time or a lower spatial resolution is required. We hypothesize the addition of a rapid 
(µs-ms) post-ionization structural separation by IM enables the ability to perform 
fragmentation of all species of interest simultaneously thus increasing the number of 
small molecules capable of being imaged without an additional sample preparation 
or an increase in analysis time. 
 The 2D separations performed by IM-MS are based on analyte ion structure 
and m/z, respectively, and is amenable to high-throughput analysis of the complex 
biological samples typically investigated during PK drug development studies.14, 15, 94, 
95 Performing drug analysis directly from dosed tissue sections by MALDI IM-MS 
provides several advantages including:  (1) separation of pharmaceutical 
compounds or metabolites from endogenous chemical noise prior to fragmentation, 
(2) simultaneous fragmentation of all species subsequent to IM separation, and (3) 
the ability to use structural isomers as internal standards (IS) for quantitation and 
image normalization.82-84 By performing fragmentation or MS/MS after IM separation, 
the td of the subsequent fragment ions correlates with the td of the parent molecule, 
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and fragment ions are separated in conformation space from other species of the 
same m/z.16, 82, 83 The limitation for simultaneous fragmentation of all species by 
MALDI IM-MS/MS is the ability to resolve the compounds of interest in the IM 
dimension. While small molecules below m/z 500 have been analyzed by IM-MS, 
studies utilizing IM-MS platforms which perform fast separations compatible with 
imaging strategies have yet to be performed. Here, we report CCS values of 
eighteen pharmaceuticals determined by MALDI drift cell IM-MS with a typical IM 
resolving power of 30 to 50. Several commonly prescribed drugs and their 
metabolites were analyzed such as anticonvulsants, antiarrhythmic agents, 
antipsychotics, ACE inhibitors, and β-blockers with a variety of molecular groups 
including benzodiazepine, 1-isopropylamino-3-phenoxypropran-2-ol, butyrophenone, 
and benzisoxazole. Additionally, simultaneous fragmentation and imaging of four 
pharmaceutical compounds by MALDI t-wave IM-MS/MS (5-15 R) was performed 
illustrating the power of this strategy to simultaneously analyze multiple small 
molecules.  
 
Results 
 
Collision cross sections of pharmaceutical compounds. The chemical structure 
and abbreviations for each analyzed drug compound are reported in Figure 29 
except for ephedrine which is shown in Figure 33. The reduced mobility (Ko) and 
CCS of eighteen pharmaceutical compounds representing several chemical classes 
were obtained by MALDI drift cell IM-MS (Figure 30, Table 10). Under the current  
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Table10.  
 
The eighteen pharmaceutical compounds analyzed and their main chemical 
moiety, m/z, Ko, and CCS.   
number name chemical group m/z Ko
a
 
drift cell 
IM-MS 
CCS (Å
2
)
a
 
1 carbamazepine benzodiazepine 237 6.51 ± 0.08 84.9 ± 0.8 
2 propranolol 
1-(isopropylamino)-3-phenoxypropan-
2-ol 
260 5.42 ± 0.02 99.7 ± 0.3 
3 atenolol 
1-(isopropylamino)-3-phenoxypropan-
2-ol 
267 5.47 ± 0.03 98.2 ± 0.6 
4 metoprolol 
1-(isopropylamino)-3-phenoxypropan-
2-ol 
268 4.85 ± 0.02 110.6 ± 0.4 
5 quinidine 6'-methoxycinchonan-9-ol 325 4.58 ± 0.03 112.8 ± 0.2 
6 clozapine benzodiazepine 327 4.52 ± 0.02 114.0 ± 0.2 
7 acebutolol 
1-(isopropylamino)-3-phenoxypropan-
2-ol 
337 4.00 ± 0.03 129.0 ± 0.6 
8 
clozapine N-
oxide 
benzodiazepine 343 4.50 ± 0.03 113.5 ± 0.4 
9 haloperidol butyrophenone 376 3.93 ± 0.03 128.2 ± 0.3 
10 enalapril L-alanine 377 3.94 ± 0.03 127.9 ± 0.4 
11 droperidol butyrophenone and benzimidazolinone 380 3.94 ± 0.03 127.5 ± 0.2 
12 spiperone butyrophenone 396 3.75 ± 0.04 133.2 ± 0.5 
13 risperidone benzisoxazole 411 3.55 ± 0.03 140.0 ± 0.2 
14 bromperidol butyrophenone 421 3.83 ± 0.02 128.3 ± 0.6 
15 domperidone benzimidazolinone 426 3.63 ± 0.03 135.6 ± 0.3 
16 paliperidone benzisoxazole 427 3.49 ± 0.04 141.5 ± 0.5 
17 fluphenazine phenothiazine 438 3.72 ± 0.03 131.2 ± 0.3 
18 sertindole phenylindole 441 3.34 ± 0.03 147.4 ± 0.3 
aCCS and Ko values are reported as the average of 10 replicate measurements. 
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MALDI drift cell IM-MS conditions, the β1-selective receptor antagonists ATE (CCS 
98.2 Å2) and MET (CCS 110.6 Å2) are easily resolved (Figure 31a). MET and ATE 
contains a 2-phenylacetamide and 4-(2-methoxyethyl)-benzene group, respectively, 
and differ by one Da with isobaric isotopic species. Current IM parameters were 
unable to resolve CLZ, an antipsychotic, from its first pass oxidized metabolite, CLZ-
NO (Figure 31b). Nevertheless, these two species are resolved in the m/z 
dimension. Further, the halogenated butyrophenone derivatives HAL and BRO were 
unable to be resolved (both exhibit CCS values of approximately 128 Å2), but the 
aromatic benzoimidazole substituted DRO (127.5 Å2) was baseline resolved from the 
phenylimidazolidin-4-one substituted SPI (133.2 Å2) (Figure 30, Table 10). 
Additionally, the structure of the atypical antipsychotic RIS differed in CCS by ~ 1 Å2 
from its main active metabolite, PAL. From the acquired data, it was calculated that 
an IM R of ~85 is required to baseline resolve these two species.  
 These results indicate that many of the small molecules were able to be 
resolved using the current IM conditions which utilize a relatively short drift cell 
length (13.9 cm) and low IM pressure (~ 3 Torr) at RT which is optimal for rapid high-
throughput sample analysis. IM-MS instruments which utilize high resolution mobility 
separations would be beneficial in the case where CLZ and its oxidized metabolite, 
CLZ-NO, were unable to be resolved and would further increase the separation of 
RIS and PAL. Thus, higher R IM would be required for the direct analysis of small 
molecules and their metabolites by MALDI IM-MS/MS while current instrumentation 
may be useful in cases where multiple drugs are dosed to simultaneously image and 
determine differences in PK due to drug-drug interactions. 
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Computational structural analysis of pharmaceutical compounds. (Performed 
in collaboration with Michal Kliman and John McLean) There were observable 
differences in the CCS values of the seven compounds analyzed above m/z 390. All 
of these compounds contain two main aromatic moieties and a linker of either two or 
three carbon atoms separating these moieties. The molecules with smaller absolute 
CCS values, SPN, BRO, DOM, and FLU, contain a three carbon atom linker while 
the two main aromatic moieties of RIS, PAL, and SER are linked by two carbon 
atoms. It was hypothesized that molecules which contain a three carbon linker are 
able to form more compact conformations due to the flexibility provided by the 
additional carbon atom to facilitate π-π stacking interactions between the two 
terminal aromatic moieties. To evaluate this computationally, the most 
representative compact and extended conformations were obtained through energy 
minimization. The computational CCS value was then determined for each compact 
and extended conformation. As expected, the experimental CCS value of each drug 
molecule occurred between the extended and compact computational CCS values 
as shown in Figure 32 where the bar represents the range of in silico CCS values 
between the two extreme conformations. Additionally, the computational CCS values 
of pharmaceutical compounds that contain a linker with three carbons have compact 
conformations with smaller CCS values than compounds with terminal moieties 
linked by two carbons. This result is consistent with the structural data obtained by 
MALDI drift cell IM-MS. 
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Simultaneous imaging of small molecules by MALDI IM-MS/MS. MALDI t-wave 
IM-MS/MS was utilized to simultaneously fragment and image four pharmaceutical 
compounds: ephedrine (EPH), PRO, SPN, and BRO (structures shown in Figure 
33a), which were each spiked into DHB matrix and spotted onto a mouse liver tissue 
section by an automatic reagent multispotter in overlapping arrays (Figure 33b). For 
the simultaneous imaging of all species, the quadrupole was used in a full scan 
mode, and all fragment ions retained the td of the original compound and are 
separated prior to entering the TOFMS. The average conformation plot for the entire 
imaging experiment is displayed in Figure 33c with the td for each imaged drug 
outlined. Notice the complexity of the spectra resulting from not only the drug 
compounds but fragmentation of all endogenous species from the tissue section as 
well. After imaging, signals corresponding to the td of each drug molecule were 
extracted to reconstruct the resulting td and m/z specific images. The average 
spectra of signals from each extracted td are displayed in Figure 33d. The average 
spectrum for all td is representative of the average spectrum acquired if IM 
separation was not utilized. EPH (m/z 166  148) is present in the average 
spectrum of td 3.3 – 3.8 ms and not in the other td specific spectra. Peaks 
corresponding to PRO (m/z 260  116) are present in the average spectrum of td 
4.0 – 4.5 ms. The average spectrum of summed signals at td 5.1 – 5.4 ms contains 
peaks corresponding to both SPN (m/z 396  165 and 262) and BRO (m/z 421  
165 and 402). While SPN and BRO are not able to be resolved by current IM 
parameters, they can be distinguished by their differing fragment ions. Additionally, 
the average spectrum of td 7.6 – 8.1 ms contains a base peak of m/z 184  
108 
 
 
109 
 
corresponding to the phospholipid head-group, the main fragment of phospholipids 
in positive ion mode. The 2D ion map of m/z of 184 at td 7.6 – 8.1 ms is displayed in 
Figure 33e. As expected, endogenous phospholipids from the tissue are present 
everywhere matrix is located except in areas where blood is abundant. 
 The td and fragment m/z specific images representing each pharmaceutical 
compound are displayed in Figure 34a. As expected, the spatial distributions of EPH 
and PRO correspond to the areas that each compound was deposited. The td 
specific images for SPN and BRO correspond to the localization of where each drug 
was spotted when images for fragment ions which distinguish both drugs are 
interrogated. When the image is reconstructed representing m/z 165 at td which 
corresponds to BRO and SPN, signal is present in locations were both SPN and 
BRO were spotted, as expected. For comparison, imaging was also performed by 
MALDI TOFMS by performing fragmentation prior to TOFMS analysis of a duplicate 
sample. No drug signal was present in MALDI TOFMS images when reported at the 
same threshold as images acquired by MALDI IM-TOFMS (Figure 34b, top). When 
the threshold is lowered by greater than 90% the signal for fragment ions of EPH, 
SPN, and BRO are non-specifically present everywhere matrix was deposited 
(Figure 34b, bottom) indicating structural specificity is lost when IM is not utilized. 
Further, at this lower threshold, the distribution of PRO signal is erroneously present 
in the area where BRO was spotted. 
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Conclusions 
 The majority of the eighteen pharmaceutical compounds were able to be 
resolved by MALDI IM-MS. With the current instrumentation, structural separation of 
CLZ and RIS from their metabolites was unable to be achieved. Here, IM-MS 
parameters with rapid separations were utilized which are compatible for imaging 
strategies but have relatively low IM resolving power. For separation of drug 
compounds and their metabolites, IM-MS parameters need to be optimized to 
increase the IM resolution (~ 85 R). 
 The pharmaceutical compounds analyzed with m/z values greater than 390 
all contain two main terminal aromatic moieties linked by either a two or three carbon 
atom chain. The compounds with a three carbon atom linker have smaller CCS 
values than those with a two carbon atom linker. It was hypothesized that three 
carbon atom linkers provide additional flexibility for aromatic stacking interactions 
between the two terminal moieties and thus a more compact conformation. 
Computational studies suggest that the number of carbon atoms present in the linker 
may be the main determinant of the gas-phase packing efficiency of these 
molecules.  
 MALDI t-wave IM-MS/MS was utilized to simultaneously fragment and image 
four pharmaceutical compounds deposited onto a liver tissue section. By performing 
fragmentation after IM structural separation the td of the original compound was 
retained by the fragment ions thus deconvoluting fragment ions. When IM separation 
was utilized the distribution of the fragment ions correlated with the location of the 
pharmaceutical compound. When fragmentation of all species was performed 
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without IM separation there was a decrease in sensitivity and erroneous distributions 
of the pharmaceutical compounds. This data indicates that simultaneous imaging of 
small molecules is possible by MALDI t-wave IM-MS with the limitation being the 
ability to separate two molecules of interest by IM. 
 
Materials and Methods 
 
Materials. HPLC grade methanol (MeOH) was purchased from Fischer Scientific 
(Pittsburgh, PA). Bradykinin (RPPGFSPFR) and 2-5 dihydroxybenzoic acid (DHB) 
were purchased from Sigma Chemical Co. (St. Louis, MO). The pharmaceutical 
compounds analyzed for this study were all purchased from Sigma Chemical Co. 
and include: clozapine, clozapine N-oxide, carbamazepine, (±)-propranolol 
hydrochloride, atenolol, (±)-metoprolol (+)-tartrate salt, acebutolol, haloperidol, 
droperidol, spiperone, bromperidol, risperidone, paliperidone, quinidine, enalapril 
maleate salt, domperidone, ephedrine, fluphenazine dihydrochloride, and sertindole.  
 
MALDI drift cell IM-MS. To obtain absolute CCS values of small molecules, 
pharmaceutical compounds were mixed with 40 mg/ml DHB in 50% MeOH and 
spotted onto a stainless steel MALDI target. Analysis was performed using a MALDI 
drift cell IM-TOFMS constructed in collaboration with Ionwerks Inc. (Houston, TX) 
and is similar to those previously described.14 Briefly, MALDI is performed by a solid-
state frequency-tripled Nd:YLF (349 nm) laser (Explorer, Newport/Spectra-Physics 
Corp., Mountain View, CA). Following ionization, ions are introduced into a 13.9 cm 
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IM drift cell maintained at a pressure of ca. 3.8 Torr He and at RT (~298 K). 
Following mobility separation, eluting ions are separated by m/z in an oTOFMS with 
a 1 m flight path maintained at 5 x 10-8 Torr (resolution, ca. 2000 to 4000).  Internal 
calibration of the MS was performed using the [M + H]+ and [2M + H]+ ions of DHB. 
The resulting 2D IM-MS data were acquired and processed using custom software 
(Ionwerks, Inc.).   
 The ion-neutral CCS (Ω) was calculated by determining the td of the ion 
packet across the IM drift cell maintained at low-field conditions. The td of an ion 
through the IM drift cell depends on ion charge and shape, the strength of the 
applied electric field (E, ~20 – 30 V cm-1 Torr-1), and the neutral drift gas temperature 
(T) and pressure (p). Ions are separated by their differing drift velocities (vd) through 
a buffer gas under an applied E using the equation: 
 
      
 
where K is a proportionality constant (or mobility) defining the ion‟s drift. For 
comparisons of IM values between drift cell IM-MS instruments, K is reported under 
conditions of STP (273 K, 760 Torr) as the reduced mobility (Ko) which is determined 
using the equation:   
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All MALDI IM-MS measurements were performed using five drift cell field strengths 
to estimate t0, a mass-dependent td correction for the time ions spend outside of the 
drift cell.95, 113 CCS values were calculated using the following equation: 
 
  
       
 
 
  
  
     
 
 
 
 
  
 
 
  
 
 
    
 
   
 
 
   
 
  
 
 
where e is the elementary charge, kb is Boltzmann‟s constant, L is the length of the 
drift cell, z is the charge state of the ion, N0 is the drift gas number density at STP, 
and mi and mn are the masses of the ion and the neutral drift gas, respectively.
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The accuracy of CCS measurements was evaluated by measuring bradykinin [M + 
H]+ ions which were always within 1.5% of 242 Å2 and is consistent with CCS values 
previously reported for bradykinin [M + H]+ ions.38    
 
In silico molecular analysis. The chemical structures of SPN, RIS, BRO, DOM, 
PAL, FLU, and SER were obtained from the ChemACX database using Chem3D 
Pro software version 10.0 (CambridgeSoft, Cambridge, MA). An extended and 
compact conformation of each drug molecule was constructed using „Molecular 
Operating Environment‟ (MOE) version 2009.09 (Chemical Computing Group Inc., 
Montreal, CA). Each  conformation was energy minimized in MOE using the Merck 
MMFF94x force field for small organic molecules.117 The computational CCS of each 
of the extended and compact conformations was determined using Sigma.39 Sigma 
determines CCS in silico using the projection model described in detail by 
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Wyttenbach et al.39  Briefly, each atom is projected as a circle with a radius specific 
to that atom onto a randomly chosen projection plane. The area of the smallest 
square which encloses the entire projected molecule is determined. Points are 
randomly picked and the ratio of those that fall within the projected molecule to those 
that fall outside multiplied by the area gives the CCS for that particular projection. 
The same steps are repeated in an iterative fashion for many randomly chosen 
projection planes, and an average CCS of all projections is calculated with user 
selected accuracy. Reported in silico CCS values are averages of three independent 
calculations.   
 
Simultaneous imaging by MALDI IM-MS/MS. Liver from a C57 adult mouse was 
dissected, flash-frozen, and stored at -80°C until analysis. Mouse liver was cut into 
12 μm sections using a cryostat and thaw-mounted onto gold-coated MALDI targets. 
Tissue sections were then placed in a desiccator for at least 20 min. For 
simultaneous imaging of small molecules, 1 mM of 1 of the 4 small molecules was 
spiked into 40 mg/ml of DHB in 50% MeOH and deposited in overlapping arrays 
onto the tissue section using a Portrait 630 (Labcyte, Sunnyvale, CA). Each spot has 
an average spot diameter of 125 μm and approximately 6 nmoles of drug per spot.   
 Simultaneous imaging of small molecules (pharmaceutical compounds) was 
performed by MALDI t-wave IM-TOFMS (SYNAPT HDMS System, Waters 
Corporation, Manchester, UK) in positive ion mode. A digital image was imported 
into MALDI Imaging Pattern Creator (Waters Corp.) to create the raster pattern for 
the imaging experiment. Imaging was performed with a 150 µm spatial resolution 
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with 600 laser shots per pixel. The wave height was linearly ramped between 2 and 
14 V with a wave velocity of 300 V and drift gas pressure (N2) of 10
-1 Torr. 
Fragmentation was performed directly after IM separation prior to TOFMS in the 
transfer region. After data acquisition, signals from td windows corresponding to 
each pharmaceutical compound analyzed were selected and exported for image 
reconstruction using DriftScope version 2.0 (Waters Corp.). Exported signals were 
converted into the Analyze file format using MALDI Imaging Converter Software 
(Waters Corp.) using a 0.1 Da bin size and visualized using Biomap (Novartis, 
Basel, CH). For comparison, imaging was repeated under the same conditions but in 
MALDI TOFMS mode with the IM gas turned off. 
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CHAPTER V 
 
CONCLUSIONS AND PERSPECTIVES 
 
Direct Tissue Analysis by MALDI Ion Mobility – Mass Spectrometry 
 Due to the complex nature of tissue samples, additional analyte separation is 
required to increase the specificity of MALDI MS for analytes of interest. To attack 
this problem, we hypothesized that a rapid post-ionization gas-phase separation by 
IM can be performed prior to MS analysis. Here, MALDI IM-MS was successfully 
demonstrated in a fully automated mode for structural and m/z separation of 
analytes directly from tissue sections. This was performed by imaging isobaric 
standards spotted directly on tissue sections which produced two different images 
(Figure 13) and by simultaneously imaging endogenous phospholipids and tryptic 
peptides from a rat brain tissue section (Figure 15). The additional structural 
separation provided by the IM dimension provides the ability to structurally separate 
isobaric species in tissue sections which may arise from:  isobaric peptides with 
multiple sequences or structures, nominally isobaric peptides and phospholipids, or 
isobaric phospholipids.  
 In addition to a gas-phase electrophoresis technique, structural information 
may be obtained in the form of a CCS directly from complex samples without analyte 
extraction or purification. The structural information provided by IM-MS can be 
acquired directly from complex samples and can be utilized prior to technologies 
which provide high structural resolution (e.g. x-ray crystallography and nuclear 
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magnetic resonance) but require large sample amounts of high purity.32, 33, 38, 40, 101 
While absolute CCS values are routinely obtained using drift cell IM-MS platforms, 
here, methods were developed and validated to obtain phospholipids and peptide t-
wave IM-MS CCS values directly from complex samples. The t-wave IM-MS CCS 
values had a high correlation with drift cell IM-MS CCS values and were used to 
evaluate the utility of MALDI IM-MS to separate different biomolecular species. 
 In addition to proteomic and lipidomic research, the post-ionization separation 
by IM is also beneficial for the analysis of exogenous molecules such as 
pharmaceutical compounds directly from tissue sections. By performing MS/MS after 
IM separation, the td of fragment ions are separated in conformation space from 
isobaric species and correlates with the td of the original molecule.
16, 82, 83 Further, 
MALDI IM-MS/MS is performed without the need for a precursor ion scan or 
additional sample preparation. The limitation of this strategy is the ability to resolve 
species of interest in the IM dimension. Here, MALDI IM-MS/MS was applied to 
perform simultaneous imaging of four small molecules spotted directly onto a tissue 
sample (Figure 33 and 34). This example illustrates the power of this technique for 
high throughput drug imaging and is applicable for studying drug-drug interactions or 
multiple metabolites simultaneously.  
 The presented research provides qualitative information on the separation of 
analytes and different classes of biomolecules by current IM-MS parameters. Even 
in cases where two species of interest were not resolved, strategies employing 
different gas compositions, IM shift reagents, or higher IM resolutions may be used 
to provide additional structural specificity.85, 118-120 Thus, the goal of this research 
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was not to provide quantitative statistical data of the degree of separation IM 
provides across different platforms but information on the amount of separation 
expected under low resolution IM conditions (5 - 50 R) with neutral IM gases (He 
and N2).  
 
Current Applications 
 
Lipid selective imaging MALDI ion mobility – mass spectrometry. Imaging 
MALDI IM-MS is especially applicable for the direct analysis of phospholipids which 
are involved in a variety of cellular processes including:  signaling pathways, protein 
sorting, energy storage, as well as forming the structural components of cell 
membranes. Here, 2D separations by IM-MS have been shown to distinguish and 
separate PC and SM species based on their CCS versus m/z correlations (Figure 
19) and separate phospholipids from peptides.26, 66 Further, selective imaging MALDI 
IM-MS analysis of phospholipids can be performed by MALDI IM-MS of disease 
tissue sections to determine altered distribution of phospholipids. For example, 
imaging MALDI drift cell IM-MS was performed on a human clear cell renal cell 
carcinoma (ccRCC) tissue section (Figure 35). Multiple phospholipid species were 
found to have different intensities across the tissue section including m/z 741 
(identified by MS/MS as [SM 16:0 + H]+) which is more abundant in the tumor than in 
the surrounding histologically normal tissue. Additionally, m/z 782, which was 
identified as [PC 34:1 + Na]+/ [PC 36:4 + H]+ by MS/MS, and 796, which was 
identified as [PC 34:2 + K]+, were found to be differentially localized.  Interestingly,  
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one can observe a drastic difference in the distribution of [PC 34:1 + Na]+ and [PC 
34:2 + K]+ even though there is only one degree of saturation difference in the fatty 
acid carbon chain. This illustrates that selective phospholipid imaging can be 
currently performed by MALDI IM-MS to provide phospholipid specific images across 
normal and disease tissue sections. 
 A current limitation of MALDI MS analysis of tissue section is that multiple 
lipid species may be present under one peak which results in erroneous images. 
Burnum et al. utilized MALDI MS/MS to determine that isobaric PE species with 
different degrees of unsaturation in the fatty acid chains are differentially distributed 
throughout day 8 mouse embryos (Figure 36).  While the MALDI MS images for PE 
36:2 and PE 38:2 showed no distinct spatial location (Figure 36, left), both were 
found by MS/MS fragmentation to consist of more than one combination of sn1 and 
sn2 fatty acids (Figure 36, right). For applications such as these, instead of 
performing MALDI MS/MS on each species of interest, MALDI IM-MS has been 
shown to distinguish isobaric lipid species by their structural differences without the 
need to perform specific MS/MS analysis.23, 77 
 
Structural internal standards for exogenous drug imaging. In addition to 
phospholipid imaging, 2D IM-MS separations are currently applicable for exogenous 
drug imaging. In particular, isobaric structural IS may be utilized to facilitate image 
normalization and quantitative imaging analysis, an area of active research in the 
pharmaceutical field. The resulting signal intensity from MS analysis of tissue  
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sections can be affected by multiple factors including the extraction efficiency of 
compounds from tissue (which may be different depending on the tissue type) and  
the ionization efficiency of the compound. Currently, an IS is spiked into the matrix 
prior to application to account for small differences in analyte signal intensity due to 
differences in sample preparation or instrument parameters between and within 
tissue sections. Typically, IMS is performed of the drug, metabolite, and IS by SRM. 
Thus, an SRM transition is monitored specifically for the IS, and the IS spectrum is 
acquired from different laser shots than the compounds of interest. Alternatively, IM 
structural separation allows an isobaric IS to be monitored from the same laser shots 
as the drug compound of interest increasing reproducibility and confidence of the 
results. 
   
Future Research Directions 
 
Peptides containing posttranslational modifications. Future research utilizing 
MALDI IM-MS will focus on the direct analysis of peptides containing PTMs from 
tissue sections. Protein PTMs may be dynamic or permanent, and change protein 
structure and/or function. The presence of PTMs is not inherently able to be 
deduced based on genomic information and is typically determined by proteomic 
studies. Further, alterations in PTMs can be a symptom or cause of disease. For 
instance, when the microtubule-associated protein, tau, becomes 
hyperphosphorylated, insoluble protein aggregates form creating the neurofibrillary 
tangles found in AD tissue.121-123 The exact role of these tangles in AD has yet to be 
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elucidated. Here, it was shown that phosphopeptides are able to be separated from 
the peptide trend-line (Figures 23 through 25). Thus, 2D IM-MS separations can be 
utilized to provide additional selectivity for low abundant phosphopeptides. Future 
studies will focus on further increasing this separation by optimizing drift gas 
composition in conjunction with higher IM R.  
 
Ion mobility selectivity based on drift gas composition. Future research will 
focus on the utilization of different drift gases to increase analyte specificity and peak 
capacity. The IM resolution is based on several parameters including the 
electrostatic field, temperature, drift gas pressure, and drift gas composition. The 
drift gas composition can be altered by both size and polarizability.85, 86, 118, 124 While 
the majority of research is focused on using N2 and He, a few papers have utilized 
novel drift gases including SF6, NH3, CO2, and CF4 in addition to the inert noble 
gases.85, 118, 125-129  Altering the drift gas has been shown to increase the IM-MS 
peak capacity for the analysis of peptides.124 Drift gas optimization is essential for 
the separation and analysis of small molecules where long-range interactions 
between analytes and neutral gas molecules have a larger effect on the analyte td 
and separation.85, 86, 118, 119, 127 For example, the small molecule chloroaniline has a 
faster td than iodoaniline in He, while in CO2 the reverse is true indicating that 
chloroanaline is affected to a greater extent by the drift gas polarizability.85  
 Methods able to directly distinguish between drug and metabolite 
enantiomers from tissue sections are needed to quickly determine the efficacy, 
safety, effects, and side-effects of each enantiomer of chiral pharmaceutical 
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compounds. Many pharmaceutical compounds are chiral, and there can be 
qualitative and quantitative differences in the activity of the two enantiomers. 
Chirality plays an important role in determining the binding, function, and distribution 
of biologically active molecules. Further, determining the PK information of each 
enantiomer can be difficult, costly, and time-consuming. Recently, by doping a chiral 
gas into the drift gas, small molecule enantiomers have been rapidly (ms) resolved 
by IM-MS.119 Figure 37 shows the gas-phase chiral separation of (S)-(-)-atenolol 
and (R)-(+)-atenolol using 10 ppm (S)-(+)-2-butanolol as the chiral modifier in N2 drift 
gas.119 While this has only been performed using high resolution IM with ESI, chiral 
imaging MALDI IM-MS would provide the ability to analyze drug and metabolite 
enantiomers without tissue homogenization, drug extraction, or chiral HPLC-MS.  
 
Advances in MALDI IM-MS instrumentation. Although imaging MALDI drift cell IM-
MS is performed in a fully automated mode to provide both structural and m/z 
resolved images, the primary remaining challenge in utilizing the MALDI drift cell IM-
MS platform is in data handling and processing. Presently only selected regions of 
2D IM-MS space are interrogated due to the large file sizes that would be generated 
in a full 5D IM-MS image (x-, y-position, ATD, m/z, and signal intensity). In molecular 
profiling experiments as demonstrated in Figure 10, a single MALDI drift cell IM-MS 
molecular profiling file is ca 20 MB. Thus, if full MALDI IM-MS spectra were saved at 
each pixel, then an image composed of 3500 pixels (the number of pixels in Figure 
14) would be approximately 70 GB using the current file format. Clearly, increasing 
the number of pixels by enhancing the spatial resolution or enlarging the field of view  
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would result in correspondingly larger files. Efforts are presently underway to 
develop new means for data storage, compression, and processing to alleviate 
these issues when data is collected on this platform.  
 For MALDI t-wave IM-MS, imaging can currently be performed by acquiring 
data from all the regions of 2D IM-MS space. Here, the primary remaining challenge 
to make this platform more widely used is to increase analyte sensitivity, decrease 
laser spot size, and increase the IM R. Additionally, software to import coordinates 
for spotted arrays and to select specific pixels to perform full scan while others are to 
perform MS/MS is required for more elaborate imaging experiments. Performing 
MALDI under higher vacuum (currently 200-300 Torr) would decrease adducts 
formed in the source and increase the S/N observed in peptide spectra. Additionally, 
the laser spot size for this platform is approximately 150 µm and decreasing the 
laser spot size would provide higher resolution imaging, and provide the ability to 
obtain more laser shots per matrix spot increasing the signal in profiling spectra. 
 Moreover, while current MALDI IM-MS instrumentation provides rapid (µs – 
ms) separations without a significant increase in experiment time, instruments 
utilized for these studies have relatively low IM resolution (5-50 R). Implementing 
high R IM instrumentation will be especially valuable for imaging of pharmaceutical 
compounds and their metabolites. For example, to resolve the pharmaceutical RIS 
and its active metabolite, PAL, an IM R of approximately 85 is calculated to be 
required. 
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Differential mobility spectrometry. Future tissue analysis by MALDI IM-MS will 
also utilize a third type of IM known as differential mobility spectrometry (DMS). 
DMS-MS provides rapid (ms) 2D post-ionization separations based on the 
interactions of analytes with the gas phase and m/z in the DMS and MS dimensions, 
respectively.15, 130, 131 DMS fractionates ions by placing alternating electric fields 
between two electrodes. Since the mobility of an ion is different in high and low 
fields, ions will drift in one of two directions perpendicular to the gas flow depending 
on the ratio of the mobility constants between the high and low fields (referred to as 
the  parameter). The deviation of the drift trajectory in one direction or the other is 
corrected by a compound specific DC offset potential (compensation voltage, CV) 
prior to the ion colliding with an electrode. Instead of acquiring the flight time of the 
ion through the chamber, the voltage required to correct the trajectory of an analyte 
is reported. The CV can be scanned to serially pass ions according to their 
differential mobility or set to a fixed value to pass only the ion species with a 
particular differential mobility. DMS-MS is able to analyze a variety of chemicals at 
low levels, including pharmaceutical compounds, and is compatible with any MS 
ionization source. Since DMS is a continuous sampling technique, it is typically 
coupled to a quadrupole or ion trap. DMS-MS instruments typically have higher 
sensitivities than other IM modalities due to their ability to refocus ions, and are 
especially applicable to analyze species from complex samples such as tissue 
sections.  
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Conclusions 
 In conclusion, the utility of IM to enhance tissue analysis was evaluated and 
provides (1) the ability to separate analytes of interest from other components in the 
sample (chemical noise), (2) simultaneous imaging and separation of phospholipids 
and peptides, (3) separation of peptides containing PTMs from unmodified peptides 
directly from complex samples, (4) structural information directly from complex 
samples in the form of an analyte CCS, and (5) simultaneous fractionation of 
multiple analytes of interest. The additional dimension of separation provides rapid 
gas-phase structural separations without a significant increase in analysis time or 
additional sample preparation.  
 The research presented here is the first occurrence illustrating direct tissue 
imaging in conjunction with 2D separations by MALDI IM-MS to resolve biomolecular 
classes and isobaric species. Methods were developed and optimized to calibrate 
and obtain MALDI t-wave IM-MS CCS values of phospholipids and peptides directly 
from complex samples such as tissue sections. Further, this research provides 
experimental results supporting fundamental theories of t-wave IM recently 
developed by Shvartzburg et al.19 Additionally, simultaneous imaging and 
fragmentation of small molecules was performed by MALDI IM-MS/MS and the 
ability of current MALDI IM-MS instrumentation to resolve small molecules was 
evaluated. It is anticipated that the impact of this technology to study underlying 
biological processes in normal and disease tissue as well as its use in drug 
development studies will be significant. 
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APPENDIX A 
 
REFERENCES OF ADAPTATION 
FOR CHAPTERS 
 
Chapter I: Sections adapted from Whitney B. Ridenour and Richard M. Caprioli. “Profiling 
and Imaging of Tissues by Imaging Ion Mobility - Mass Spectrometry.” Ion Mobility 
Spectroscopy - Mass Spectrometry:  Theory and Applications. Ed. Charles Wilkins and Sarah 
Trimpin. Boca Raton:  CRC Press, 2010. 
 
Chapter II: Sections adapted from John A. McLean, Whitney B. Ridenour, and Richard M. 
Caprioli. Profiling and Imaging of Tissues by Imaging Ion Mobility - Mass Spectrometry. 
Journal of Mass Spectrometry 2007, 42(8): 1099-105. 
 
Chapter III: Sections adapted from Whitney B. Ridenour, Michal Kliman, John A. McLean, 
and Richard M. Caprioli. Structural Characterization of Phospholipids and Peptides Directly 
from Tissue Sections by MALDI Traveling-Wave Ion Mobility - Mass Spectrometry. 
Analytical Chemistry 2010, 82(5): 1881-9. 
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